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STRESS-ACTIVATED MIG6 COMPROMISES HEPATIC METABOLISM 
DURING DIET-INDUCED OBESITY 
Obesity-induced hepatic fat accumulation or nonalcoholic fatty liver 
disease (NAFLD) is the leading cause of liver disease in the United States. 
Unfortunately, NALFD patients are at higher risk of cardiovascular disease and 
mortality. The development of hepatic steatosis is multi-factorial and leads to a 
variety of pathologies. Yet, the molecular mechanisms behind liver disease 
during hepatic fat accumulation remain unclear. Here, we describe novel 
mechanisms of impaired liver function in the context of obesity-induced hepatic 
stress. Using chemical- and fatty acid-induced endoplasmic reticulum (ER) 
stress, we discovered ER stress decreases the activation of the pro-growth, pro-
survival, receptor tyrosine kinase, epidermal growth factor receptor (EGFR) in 
vitro. Importantly, EGFR was inhibited during these stress conditions by the 
induction and stabilization of mitogen inducible gene 6 (Mig6). Furthermore, Mig6 
knockdown in vitro enhanced EGFR signaling and promoted survival. 
We demonstrated that mice fed a high fat diet have decreased EGFR 
activation and increased Mig6 protein expression, likely due to obesity-induced 
ER stress. To determine the functional consequences of increased Mig6 
expression, we generated Mig6 liver-specific knockout mice (Mig6 LKO) and 
subjected them to high fat feeding. During diet-induced obesity, Mig6 LKO mice 
had improved hepatic glucose tolerance despite no improvements in whole-body 
insulin sensitivity or insulin secretion. Hepatic insulin signaling, measured by AKT 
vi 
activation, was similar between Mig6 LKO and littermate controls. However, 
several insulin-sensitive genes involved in gluconeogenesis were altered in Mig6 
LKO mice compared to controls. In addition, Mig6 LKO mice had higher plasma 
high density lipoproteins and triglycerides despite similar liver lipid content. Using 
RNA sequencing we discovered Mig6 regulates several metabolic pathways in 
liver. These findings indicated Mig6 not only controls hepatic growth and survival 
but also regulates metabolism. This work will help us to better understand how 
augmented growth factor signaling impacts metabolic regulation during 
pathological obesity.  
Patrick T. Fueger, Ph.D., Chair 
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CHAPTER 1: INTRODUCTION 
Preview 
Obesity-induced liver disease: The global obesity epidemic is 
associated with increased morbidity and mortality, and despite the 
consequences, over 35% of the United States population remains obese (Flegal 
KM et al., 2012; Isomaa et al., 2001; Mokdad AH et al., 2003). Several theories 
naming obesogenic causes exist, including but not limited to: sedimentary life 
styles, genetic predisposition, environment, gestational environment, food 
additives and sweeteners, and even vaccines (Boney et al., 2005; England, 
2012; Hales and Barker, 1992; Jebb and Moore, 1999; Lim et al., 2010). Though 
most explanations are backed by extensive research, the culprit is likely 
multifactorial. So why does the obesity epidemic matter? Because as the 
waistline grows, so do the pathological consequences of obesity. In fact, waist 
circumference is significantly associated with increased risk of cardiovascular 
disease (CVD) (Koning et al., 2007).  
Obesity arises when substrate ingestion and absorption outpace the 
body’s metabolic capacity to utilize substrate as energy. Most excess substrates 
(monosaccharides, amino acids, and fat droplets) are absorbed in the intestines 
and stored in muscle, adipose, and liver. Because fats have the lowest 
thermogenic cost (i.e., the amount of energy needed to absorb, metabolize, and 
store), they are the preferred storage substrate in the postprandial state (Jéquier, 
2002; Coppack et al., 1990). In healthy individuals, a majority of dietary fats are 
stored in the adipose tissue (Coppack et al., 1990). However, as obesity 
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increases and adipose tissue reaches its maximum storage capacity, fats are 
displaced to alternate storage depots, mainly the liver. In this context, the liver 
gains >5% of its weight in fat and may develop fatty liver disease, which, in the 
absence of alcohol use, is known as non-alcoholic fatty liver disease (NAFLD). 
Patients susceptible to NAFLD are at higher risk for CVD, and the severity of 
CVD increases with severity of NAFLD (Volzke et al., 2005; Targher et al., 2006). 
Moreover, patients with NAFLD are at an increased risk for postoperative 
complications following hepatectomy or resection surgeries (McCormack et al., 
2007). 
Although not all NAFLD is due to obesity, obese individuals have a higher 
prevalence of NAFLD. NAFLD ranges from simple steatosis (defined as hepatic 
fat content >5%) to nonalcoholic steatohepatitis (NASH) and cirrhosis (Kleiner et 
al., 2005). This excess hepatic fat creates insulin resistance, oxidative and 
endoplasmic reticulum (ER) stress, and inflammation. Fortunately, the liver has 
several intrinsic mechanisms to repair damage caused by these stressors. 
However, during obesity, many of these pathways become compromised and 
ultimately affect physiology, and in susceptible populations, may lead to liver 
failure. Therefore, the following sections will explore the regulation of hepatic 
metabolism under physiological conditions, the hepatic pathological 
consequences associated with obesity, and the endogenous repair mechanisms 
that restore hepatic function following insults.  
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Metabolic regulation 
Insulin action in extra hepatic tissue: Dietary ingestion of 
carbohydrates, hepatic glucose production (HGP), and elevations in free fatty 
acids cause insulin release by the pancreatic β-cell. This process is enhanced by 
incretin hormones, most notably GLP-1 and GIP, and inhibited by the 
counterregulatory system, most notably glucagon and the catecholamines 
epinephrine and norepinephrine (Vilsbøll and Holst, 2004). Insulin lowers plasma 
glucose both indirectly through brain circuitry and directly through its anabolic 
action on several tissues. Insulin consists of two polypeptide chains and is 
released as a hexamer held together by a zinc ion from highly regulated granular 
exocytosis (Smith et al., 1984). Insulin lowers blood glucose through three main 
metabolically active tissues skeletal muscle, adipose, and liver. In most tissues, 
insulin binds to the insulin receptor, a receptor tyrosine kinase (RTK), at the 
cellular membrane, activates dimerization, and through subsequent 
conformational changes transactivates the intracellular kinase domains resulting 
in tyrosine phosphorylation. Activated insulin receptors elicit a majority of 
metabolic responses through the binding of IRS1/2 PH domain containing 
adaptor proteins. The active receptor may also bind SHC, GAB1, GAB2, and 
SH2B, among other adaptor proteins. Once bound, IRS1/2 is phosphorylated and 
binds PI3K, which converts membrane bound PI(4,5)P2 into PI(3,4,5)P3. 
PI(4,5)P2 conversion represents a key regulatory step in insulin signaling, as 
PTEN dephosphorylates PI(3,4,5)P3 back into PI(4,5)P2 thereby terminating 
signaling. The resultant membrane bound signaling intermediates recruit AKT1/2 
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for phosphorylation on Thr308 and Ser473 via PDK1 (White, 2003). AKT1/2 
activation is a key regulator of both metabolism and growth. AKT1/2’s importance 
in growth and development is evident by embryonic lethality of whole body 
knockout animals (Dummler et al., 2006), and dual liver-specific ablation of both 
AKT1 and AKT2 reveals AKT1/2 as a master regulator of metabolism through 
phosphorylation of several key metabolic intermediates (Lu et al., 2012). Indeed, 
AKT1/2 exerts most of its metabolic response by phosphorylation of FOXO1, 
GSK3β, and mTORC1. Both the regulation and actions of AKT1/2 are tissue and 
context specific.  
Insulin also stimulates the storage of glucose as glycogen through 
AKT1/2-mediated phosphorylation of GSK3β and subsequent activation of 
glycogen synthase in both skeletal muscle and liver. In fact, one third of dietary 
glucose is stored in skeletal muscle (M J Pagliassotti and Cherrington, 1992), 
where insulin promotes its uptake through AKT1/2 phosphorylation of AS160 and 
GLUT4 glucose transporter translocation to the membrane. In addition to its 
direct effects on peripheral tissues, insulin activates vascular delivery of glucose, 
a process that becomes diminished during insulin resistance and in type 2 
diabetes mellitus (T2DM).  
In the post-prandial state, insulin action on adipose tissue also stimulates 
GLUT4 translocation to the membrane; though its main effect is through 
suppression of lipolysis and uptake of fatty acids for storage as triglycerides. 
Activation of the insulin receptor in adipose tissue inhibits PKA activation and 
decreases hormone sensitive lipase activity (lowers lipolysis) while activating 
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acetyl-coA carboxylase and fatty acid synthase for fatty acid synthesis (Giorgino 
et al., 2005). Thus insulin creates an anabolic environment in adipose tissue 
depots. 
Control of metabolism through substrates and hormones in liver: 
Substrate concentration plays a critical role in the regulation of acute metabolic 
shifting from the fed to the fasting state in the liver. The ability of substrates to 
control metabolism, however, are mediated by the environment in which they are 
created. For example, hepatic glucose uptake and production are regulated by 
acute metabolic intermediates as well as hormonal control of enzymatic gene 
transcription. The two main hormones in hepatic metabolism are insulin and 
glucagon. Hepatic insulin action has a multitude of responses. First, insulin 
signaling transitions the liver from a catabolic to an anabolic state by activating 
glycolytic and suppressing gluconeogenic gene expression. Second, insulin 
activates glycogen synthesis and thus stores glucose. Last, insulin signaling 
initiates de novo lipogenesis and promotes β-oxidation. In contrast, the main 
counterregulatory hormone glucagon opposes these effects through cAMP 
activated PKA. 
Glucose regulation in liver: The liver constitutively expresses the 
GLUT2 transporter which has a high KM allowing maximum glucose entry into the 
hepatocyte. Because GLUT2 can transport glucose bilaterally, the liver must 
“trap” glucose by phosphorylation into glucose-6-phosphate (G6P) by 
glucokinase. Despite the presence of an enzymatic system to reverse this 
trapping step, phosphorylation of glucose represents a critical step in hepatic 
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glucose uptake and is highly regulated. Glucokinase is indirectly regulated by the 
binding of glucose to glucokinase regulatory subunit, thereby freeing glucokinase 
and allowing its translocation from the nucleus to the cytosol. Both glucokinase 
transcription and activity are increased by insulin, and its expression and activity 
are decreased in insulin resistant states (Katz et al., 1979). 
Following “glucose trapping” the fate of G6P is dependent on fasting vs. 
fed states. Postprandial G6P is converted to glycogen, enters glycolysis, and in 
small quantities converted to fatty acids. In contrast, in the fasted state, G6P is 
hydrolyzed by glucose-6-phosphatse (G6Pase) into glucose for release into the 
blood stream. G6Pase is transcriptionally activated by cAMP signaling (from 
glucagon and other counterregulatory hormones) and repressed by insulin 
(Argaud et al., 1996; Nordlie and Snoke, 1967). Another important switching 
point in HGP is mediated by phosphoenolpyruvate carboxykinase’s (PEPCK) 
conversion of the tricarboxylic acid (TCA) cycle intermediate oxaloacetate into 
phosphoenol pyruvate for use in gluconeogenesis. PEPCK is transcriptionally 
activated by glucagon and glucocorticoids, yet inhibited by glucose and insulin 
(Scott et al., 1998). 
Hormone-mediated transcriptional control of gluconeogenesis is regulated 
through forkhead transcription factor 1 (FOXO1) and peroxisome proliferative 
activated receptor-γ co activator 1 (PGC-1α). As previously stated, FOXO1 is 
deactivated by insulin mediated activation of AKT1/2 and subsequent 
phosphorylation and nuclear exclusion. Activated FOXO1 is a transcription factor 
for gluconeogenic genes such as PEPCK, G6Pase, and fructose-1,6-
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biphosphatase (Gross et al., 2008). PGC-1α is also a transcription factor for 
gluconeogenic genes like PEPCK and PGC-1α and is activated through cAMP 
signaling (Puigserver et al., 2003). 
Lipid regulation in liver: Like glucose metabolism, hepatic lipid 
metabolism is also regulated by both substrate and hormonal cues. Foremost, 
the liver secretes bile acids which aid in dietary absorption of lipids through 
formation of mixed micelles. Following lymphatic uptake, substrate availability is 
facilitated in fenestrated hepatic capillary beds and hepatic sinusoidal spaces 
allowing hepatocellular surface lipases unrestricted access to lipid trafficking 
particles. Once removed, free fatty acids (FFAs) are transported across the 
membrane through several types of transporters, including the fatty acid 
transport proteins FATP and CD36. The remaining source of hepatic lipids 
comes from dietary fat absorption through remnant ApoE bound chylomicrons 
and hepatic de novo lipogenesis, where carbons from glucose are converted into 
fatty acid chains (Donnelly et al., 2005). 
Upon crossing the hepatic membrane, non-esterified fatty acids (NEFAs) 
are rapidly converted to acyl-CoAs by the FATP and fatty acyl-CoA synthases 
(Kawano and Cohen, 2013). The fate of cytosolic acyl-CoAs varies depending on 
the metabolic state of the liver. Acyl-CoAs themselves may act as signaling 
intermediates directly affecting hepatic metabolism by inhibiting glucokinase and 
pyruvate dehydrogenase, among many others metabolic enzymes (Faergeman 
and Knudsen, 1997). Acyl-CoAs are also transported into the mitochondria via 
conversion to acyl-carnitine by carnitine palmitoyl transferase (CPT) proteins for 
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TCA cycle utilization or conversion to ketone bodies. In insulin-sensitive 
hepatocytes, acyl-CoAs are converted into triglycerides (TG) and packaged for 
secretion in VLDL; however, insulin resistance causes increased storage in the 
form of TG droplets within the hepatocyte.  
Insulin signaling activates de novo lipogenesis through coordinated and 
comprehensive changes in gene transcription. As mentioned previously, insulin 
signaling activates PI3K which controls lipogenesis through two main pathways. 
First, AKT2 phosphorylates and inhibits FOXO1 and PGC-1α, thus removing 
transcriptional restraint on lipogenic genes (Perry et al., 2014). AKT1/2 also 
activates SREBP-1c processing and subsequent nuclear localization for lipogenic 
gene expression (Yecies et al., 2011). AKT1/2-mediated FOXO1 activity also 
regulates several lipogenic genes including ACC, and FAS (Zhang et al., 2006). 
Together these transcriptional changes promote the conversion of carbons from 
glucose into lipids for presumably long-term storage.  
NAFLD and hepatic pathologies 
NAFLD: NAFLD and its spectrum of diseases afflicts one in every three 
adults in the U.S. and 25% of the global population (Browning et al., 2004; 
Younossi et al., 2016). NAFLD begins with inappropriate hydrocarbon storage of 
fat (mainly TG) in hepatocytes. These hydrocarbons originate from both hepatic 
and extra-hepatic sources. A majority of the carbons utilized in hepatic TG 
synthesis originate form insulin-resistant adipose tissue (Donnelly et al., 2005). 
Insulin resistance causes inappropriate lipolysis and transfer of NEFAs to the 
serum pool (bound to albumin) or converted into TGs for transport in lipoproteins. 
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As previously mentioned, a large portion of the population has the ability to store 
lipids in the liver without pathological consequences (benign steatosis). However, 
estimates as high as 25% of NALFD patients progress to NASH, and fewer still, 
proceed to fibrosis with cirrhosis and eventual liver failure (Dixon et al., 2001). 
Although only a small percentage of NAFLD patients fully progress towards liver 
related death, the sheer number of NALFD patients globally will translate to over 
20,000,000 liver related deaths among current NAFLD patients (Rinella and 
Charlton, 2016). The transition towards NASH often requires a second “hit” as 
proposed by Day and James in 1998. Whether the secondary hit is required or 
not, several stressors occur in the context of NAFLD. These stressors arise from 
lipotoxins and included insulin resistance, oxidative and endoplasmic reticulum 
(ER) stress, and inflammation (Day and James, 1998; Neuschwander-Tetri, 
2010). 
Insulin resistance: An early pathology of obesity is whole-body insulin 
resistance. Insulin resistant diabetes (T2DM) was first noted by Falta and Boller 
in 1931 and later confirmed by Himsworth in 1936. Each group noted different 
responses in plasma glucose when patients were given a mixture of glucose and 
insulin. The patients either exhibited lowered plasma glucose and ketosis, or 
elevated plasma glucose regardless of an insulin co-infusion (Falta and Boller, 
1931; Himsworth, 1936). Since the early studies over the last century, the 
mechanisms of insulin resistance have been broadly defined.  
Calorie intake per capita has increased by 20% over the past three 
decades (Guyenet and Schwartz, 2012). Chronic increases in caloric intake 
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cause increased insulin secretion and resistance to insulin in multiple tissues. In 
the hypothalamus, reduced insulin receptor expression leads to hyperphagia and 
fat mass gain in rats (Obici et al., 2002a). More importantly, several diet-induced 
obesity models display inflammatory-mediated hypothalamic insulin resistance 
(De Souza et al., 2005; Obici et al., 2002b; Posey et al., 2009). Perhaps more 
studied than insulin in hypothalamic signaling is the functions of adipose-derived 
leptin. Leptin limits food intake and adiposity and affects multiple tissues. Leptin 
release correlates with adiposity levels in mice and humans suggesting systemic 
leptin resistance (Maffei et al., 1995).  
In addition to leptin, adipose tissue secretes a large array of metabolic 
hormones – the so-called adipokines. Adipose expansion leads to recruitment of 
pro-inflammatory macrophages and increased secretion of pro-inflammatory 
cytokines such as TNF-α, IL-6, and IL-1β (Spranger et al., 2003). These 
cytokines initiate insulin resistance, thereby increasing lipolysis and reducing 
glucose uptake. The release of cytokines and FFA into the blood stream affects 
peripheral tissues, including skeletal muscle and liver. In muscle, insulin 
resistance impairs GLUT4 translocation and reduces glucose uptake, thus 
increasing plasma glucose levels.  
In mouse liver, genetic ablation of the insulin receptor (LIRKO mouse) 
yields hyperglycemia, glucose intolerance, and insulin resistance (Michael et al., 
2000). Furthermore, high-dose hyperinsulinemic-euglycemic clamp studies in 
LIRKO mice reveal compromised HGP suppression despite maintaining insulin’s 
ability to suppress FFAs (Fisher and Kahn, 2003). As previously discussed, 
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hepatic lipid storage increases during obesity. The FFAs entering the liver are 
esterified and stored as triglycerides. However, a subset of lipids become 
diacylglycerols (DAG), which activate atypical protein kinase C isoforms (PKC) 
(Samuel et al., 2007). PKCs are implemented in direct inhibition of insulin 
signaling through serine phosphorylation in response to nutrient overload (Perry 
et al., 2014). In addition to PKC, the MAPK, JNK, is activated during obesity-
induced stress and directly inhibits insulin signaling through serine 
phosphorylation of IRS1/2 (Nakatani et al., 2004; Ozcan et al., 2004). The 
inhibition of hepatic insulin signaling leads to unrestricted glucose production 
accelerating the elevated plasma glycaemia associated with insulin resistance.  
Hepatic oxidative stress: A major player in obesity-induced hepatic 
stress is oxidative stress caused by the by-products of β-oxidation and 
inflammation. Physiologically, the liver has an incredible capacity for lipid 
turnover during fed-fasting cycles (turnover equals ~80 and 10%/h in mice and 
humans, respectively) (Otero et al., 2014). The mitochondria utilizes β-oxidation 
to generate reducing equivalents (NADH and FADH2) for the electron transport 
chain for oxidative phosphorylation and subsequent ATP generation (Serviddio et 
al., 2011). Under physiological conditions, liver oxidative phosphorylation 
generates reactive oxygen species (ROS) albeit in relatively small quantities 
compared to skeletal muscle (St-Pierre et al., 2002). Liver ROS, such as 
superoxides, are rapidly converted to H2O2 by superoxide dismutase and form 
adducts with lipid chains to form 4-hydroxynonenal (Esterbauer et al., 1991). 
Therefore, any increase in FFA concentration causes an increase in β-oxidative 
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and therefore ROS. In fact, studies in NAFLD patients reveal an increase in both 
hepatic β-oxidation and oxidative stress (Miele et al., 2003; Narasimhan et al., 
2010). 
Oxidative stress is often referred to as the “secondary hit” in the 
development of NASH (Day and James, 1998). ROS generation in NAFLD 
causes the activation of inflammation, DNA damage, and even cell death. Mice 
fed a methionine choline deficient diet (MCD, a model of NASH) develop 
increased oxidative stress and subsequent cytochrome 2E1 expression, which 
further exacerbates ROS production (Weltman et al., 1996). Although the MCD 
diet is not a bona fide model of insulin resistance (Rinella and Green, 2004), it 
activates inflammatory pathways through NFκB signaling and leads to DNA 
damage (dela Peña et al., 2005; Gao et al., 2004). Importantly, ROS, 
inflammation, and DNA damage are all well-documented pathologies of NASH 
development in human patients (Kleiner et al., 2005; Narasimhan et al., 2010; 
Tanaka et al., 2013). Further still, apoptosis is present in patients with NASH and 
correlates with the severity of the disease (Feldstein et al., 2003; Wieckowska et 
al., 2006). 
Hepatic ER stress: Forty percent of hepatic transcripts encode secreted 
proteins (Uhlén et al., 2015). In fact, albumin is secreted at a rate of 18 g/d, or 
about 1% of total liver weight is secreted as albumin each day (Molina and 
DiMaio, 2012). Therefore, the liver must maintain a massive capacity to 
synthesize, properly fold, and secrete proteins. The endoplasmic reticulum (ER) 
is the site of major protein folding and quality control for the tertiary structures of 
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membrane bound and secreted proteins (Mori, 2000). Several mechanisms have 
evolved to ensure proper ER function, mostly notably the unfolded protein 
response (UPR). 
The canonical UPR: The ER environment is highly enriched in Ca2+, 
chaperone proteins (Bip/GRP78, and GRP94), and isomerase, all of which are 
conducive towards proper protein folding (Fu et al., 2012; Mori, 2000). Upon 
sensing unfolded or misfolded proteins, the ER activates the UPR through three 
different ER membrane bound signaling arms: IRE1α/β, PERK, and ATF6. Upon 
sensing unfolded proteins, the chaperone Bip is released from both IRE1α/β and 
PERK. These kinases are phosphorylated leading to complex downstream 
signaling pathways. For example, activated IRE1α/β causes splicing of XBP1 
mRNA allowing for translation into XBP1s transcription factor leading to 
expression of DnaJ/Hsp-like chaperone genes (Lee et al., 2003). In addition, 
IRE1α/β and PERK kinase activity phosphorylate JNK and IKK leading to 
inflammatory responses (Hu et al., 2006; Urano et al., 2000). More importantly, 
both JNK and IKK have been implicated in IRS1/2 serine phosphorylation linking 
ER stress to insulin resistance (Hirosumi et al., 2002; Gao et al., 2002). In 
addition, active PERK phosphorylates and inactivates the eukaryotic initiation 
factor 2 alpha (eif2α) leading to global translation blockade with the exception of 
genes involved in ER stress repair (Harding et al., 1999). Together IRE1α/β and 
PERK activate repair programs and inhibit global protein synthesis until 
misfolding or stress can be remedied. The third arm of the UPR pathway ATF6 is 
a transcription factor rendered inactive in the ER membrane. Upon stress, ATF6 
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is reduced and translocated to the Golgi where it is cleaved and further 
translocated to the nucleus where it becomes transcriptionally active for both 
chaperone and inflammatory mediators (Shen et al., 2002). ATF6 can also 
interact with XBP1s, and together regulate the transcriptional response of the 
UPR (Wu et al., 2007). The UPR is not only intended to alleviate ER stress 
caused by misfolded proteins but has recently been implicated in metabolic 
regulation. 
UPR and hepatic metabolism: The UPR evolved to alleviated ER stress, 
however, the hepatic UPR also regulates metabolism, specifically through 
substrate control. Notably, ER stress is activated during physiological cycles of 
feeding and fasting and genetic and diet-induced obesity mouse models 
(Oyadomari et al., 2008; Ozcan et al., 2004). More importantly, ER stress is 
detected in human liver samples from NAFLD and NASH patients (Puri et al., 
2008). As previously stated, chronic UPR activation increases insulin resistance 
through serine phosphorylation of IRS1/2 and activation of inflammatory 
mediators, which exacerbate insulin resistance leading to changes in hepatic 
metabolism (Ozcan et al., 2004). Importantly, hepatic ER stress is well 
established in both diet and genetic models of obesity (Ozcan et al., 2004). 
Additionally, ER stress induces both G6Pase and HGP in vivo and in vitro 
(Gonzales et al., 2008; Wang et al., 2006a). The change in HGP and G6Pase 
expression can be alleviated by overexpression of the ER chaperone protein 
ORP150 in db/db mice (Nakatani et al., 2005). Recently, ATF6α has been 
reported to suppress G6Pase gene expression resulting in lower HGP; however, 
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during sustained obesity-induced ER stress, ATF6α expression is lost (Seo et al., 
2010). Interestingly, the CREB coactivator, CRTC2 (mTORC2) has been shown 
to bind ATF6α thereby inhibiting HGP restrainment (Wang et al., 2009). This 
interaction is of note because CRTC2 is activated during fasting and increases 
gluconeogenic genes including PEPCK and G6Pase (Cornu et al., 2013). In 
addition to ATF6, PERK and IRE1α/β affect hepatic metabolism. For instance, 
mice with an active mutation in eIF2α, part of the PERK pathway, are extremely 
hypoglycemic and have impaired expression of gluconeogenic genes (Scheuner 
et al., 2001). Moreover, XBP1s haploinsufficient mice fed a HFD exhibit weight 
gain, fasting hyperglycemia, and impaired glucose and insulin tolerance (Ozcan 
et al., 2004). 
Lipid metabolism is also affected by the UPR pathways. In fact, hepatic 
XBP1 disruption lowers the expression of the lipogenic genes DGAT2, ACC2, 
and SCD1 (Lee et al., 2008). Disruption of eIF2α phosphorylation prevents 
activation of PPARγ and FAS-mediated lipogenesis in response to a HFD 
(Oyadomari et al., 2008). Furthermore, overexpression of the ER chaperone Bip 
in genetically obese mouse models lowers SREBP-1c activation and improves 
glucose and lipid homeostasis (Kammoun et al., 2009). The alterations in both 
gluconeogenesis and lipogenesis coincide with the ER’s central role in hepatic 
metabolic regulation.  
The ER is the site of G6Pase system and therefore, the major site for 
regulation of HGP. During ER stress, the ER membrane must expand to harbor 
misfolded proteins and the chaperones, foldases, and degradation transporters 
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responsible for recovery. Thus, lipogenesis itself may accommodate the 
membrane expansion required to mount an appropriate recovery response to ER 
stress. 
ER stress-mediated cell death: The UPR is designed to alleviate 
intracellular stress; however, chronic ER stress can precipitate the induction of 
apoptosis through several ER stress pathways. For example, IRE1α activates 
JNK, which phosphorylates and inactivates pro-survival factor Bcl2 and activates 
pro-apoptotic Bim leading to intrinsic apoptosis (Lei and Davis, 2003). Much of 
the cell death associated with ER stress is attributed to C/EBP-homologous 
protein (CHOP) through ATF4 expression. Indeed, diets high in fats or sucrose 
lead to increased CHOP and Bip expression and increased cell death, as 
indicated by cleaved caspase 3 activity (Wang et al., 2006b). Chop knockdown in 
liver cell lines reduces palmitate-induced caspase 3 activity (Pfaffenbach et al., 
2010). Alternatively, CHOP deficient mice have improved liver injury following 
bile duct ligation though inhibition of pro-apoptotic BAX and reduced DNA 
damage (Tamaki et al., 2008). Though CHOP-deficient mice have similar liver 
injury in response to MCD diet, a model of NASH (Pfaffenbach et al., 2010). In 
addition to CHOP and JNK activity, ER Ca2+ dyshomeostasis occurs with fatty 
acid-induced ER stress, and likely contributes to apoptosis (Wei et al., 2009). 
Mechanisms of hepatic repair: Hepatocytes maintain the capacity to 
proliferate following tissue injury or loss. For example, during liver resection, viral 
infection, or toxic stress, the remaining healthy hepatocyte population will expand 
to compensate for physical or functional loss. Several studies using mice 
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overexpressing plasminogen activator (a model of chronic liver injury) 
demonstrated that healthy or transplanted hepatocytes will undergo several 
rounds of proliferation in order to meet whole-body metabolic demand (Rhim et 
al., 1994, 1995; Sandgren et al., 1991). Moreover, in dogs, transplanted livers will 
either expand or contract to meet the metabolic demands of the recipient (Kam et 
al., 1987). The same is true for liver transplants in rats gradually proliferating until 
optimal size is reached (Francavilla et al., 1994). Stressed liver cells, however, 
may not possess the full ability to respond appropriately when challenged. For 
example, human patients with steatosis are more likely to suffer perioperative 
complications following liver resection than healthy patients, though these effects 
may be remnant of reduced hepatic secretion of clotting factors (Kooby et al., 
2003). Thus, steatosis itself may limit the regenerative and repair potential of 
hepatocytes. 
Triggers of hepatic regeneration: Following injury due to hepatotoxins 
or resection, inflammatory cytokines must “prime” the liver for regeneration, as 
first proposed by Fausto et al. The priming phase is required for full DNA 
replication by initiating the transition from quiescent G0 to G1 (Webber et al., 
1994; Fausto et al., 2006). TNF-α and IL-6 are the primary cytokines responsible 
for inflammatory signaling through activating protein 1, STAT3, and NFκB. 
Inflammatory signaling is required to activate parenchymal proliferation following 
loss (Akerman et al., 1992; Cressman et al., 1996). In addition to cytokines, bile 
acids, amino acids, and inflammatory lipids, promote repair following injury. 
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However, mitogens and their receptors are vital to the regenerative capacity of 
hepatocytes and their significance will be outlined below. 
Mitogens and their receptors: Mitogens include a large family of soluble 
proteins that act through autocrine, paracrine, and endocrine signaling. The 
primary mitogens involved in hepatic function (including repair, regeneration, 
growth, and metabolism) are insulin, HGF, TGF-α, HB-EGF, EGF, β-catenin, and 
many others. Insulin’s role in hepatic function is primarily though metabolic 
regulation and was previously discussed. β-catenin signaling is implicated in 
repair and organogenesis but will not be outlined here. The remaining mitogens 
activate receptor tyrosine kinases (RTKs) and are directly involved in hepatic 
repair following injury and are outlined below. 
Mechanical stress on hepatocytes releases several ligands associated 
with repair. For example, mechanical stress or tissue damage activates 
metallopeptidases releasing growth regulators (TGF-β) and mitogens (EGF, HB-
EGF, and HGF) into the circulation or through paracrine action. These ligands act 
primarily through the epidermal growth factor receptor (EGFR) family. In fact, the 
secretion and circulating concentration of many EGFR ligands and subsequent 
hepatic EGFR activation increases following partial hepatectomy in mice 
(Berasain et al., 2005; González et al., 2010; Ito et al., 1994; Jones et al., 1995; 
Kiso et al., 1995; Mead and Fausto, 1989; Zerrad-Saadi et al., 2011). 
Epidermal growth factor receptors and ligands: In hepatocytes, the 
major RTKs that governs cell proliferation and survival is the EGFR family. EGFR 
family members are activated by several ligands including EGF, TGFα, 
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amphiregulin, and HB-EGF (Berasain et al., 2005; Ito et al., 1994; Kiso et al., 
1995; Natarajan et al., 2007; Paranjpe et al., 2010). There are four main EGFR 
family members EGFR, and ErbB 2-4. ErbB-2 and -4 have catalytically active 
cytosolic domains similar to EGFR, whereas ErbB-3 is catalytically inactive. 
Adding to the complexity, EGFR family members can form both homo- and 
heterodimers upon ligand activation (Bose and Zhang, 2009; Schlessinger, 
2002). Studies in rat liver and rat hepatoma cells demonstrate preferential 
expression of EGFR and ErbB-3, with low expression levels of ErbB-2, whereas 
mouse liver samples contain the highest level of EGFR (Carver et al., 2002; 
Onuma et al., 2009). Given the expression patterns and plethora of studies 
revealing the importance of EGFR in hepatic regeneration, we chose to focus on 
EGFR. 
In isolated mouse hepatocyte studies, EGFR initiates proliferation by 
inducing cyclins and suppressing cyclin dependent kinase inhibitors, which 
together promote the G1-S phase transition (Collin de l’Hortet et al., 2012). Of 
note, cell cycle activation requires priming by cytokines, as previously mentioned. 
Conversely, inhibiting EGFR activation increases cellular caspase 3/7 activity, 
decreases viability, and reduces expression of pro-survival factors including Bcl-2 
and Survivin (Paranjpe et al., 2010; Schiffer et al., 2005). Thus, EGFR signaling 
can control hepatocyte proliferation and the balance between cell survival and 
death through multiple mechanisms. 
Under normal conditions, total hepatic mass is tightly protected; when a 
loss of hepatic tissue occurs, the liver (and other organs) responds by initiating 
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programs (e.g., EGFR signaling) aimed at increasing the numbers of 
hepatocytes. Studies using liver-specific EGFR ablation demonstrate EGFR is 
required for complete liver regeneration and activation of the stress response 
kinase p38 following partial hepatectomy (Natarajan et al., 2007). Additionally, 
shRNA-mediated knockdown of EGFR in hepatectomized rat liver reduced BrdU 
labeling and gene expression of several cyclins. Alternatively, these mice exhibit 
increased expression of pro-apoptotic genes such as BID, and Bak1, and 
activates caspases 3/7 while reduced expression of the pro-survival gene 
Survivin (Paranjpe et al., 2010).  
Several signaling cascades emanating from RTKs regulate cell 
proliferation and survival, and these pathways may become compromised during 
conditions of stress (Achard and Laybutt, 2012; Hotamisligil, 2010; Wang et al., 
2006b). Pathologically, hepatic EGFR signaling is decreased in mouse models of 
obesity, and following partial hepatectomy, the regenerative response in these 
mice is impaired (Collin de l’Hortet et al., 2014). Importantly, in both mice and 
human liver tissue, EGFR expression has been negatively correlated with 
steatosis. Steatosis negatively affects postsurgical outcomes in human patients 
following partial hepatectomy and is associated with increased hepatic apoptosis 
(Collin de l’Hortet et al., 2014; McCormack et al., 2007; Wieckowska et al., 2006). 
Unfortunately, the mechanisms for obesity-impaired regeneration and survival as 
well as hepatic EGFR dysfunction are not well known.  
EGF regulation of metabolism: EGF is produced by the submandibularly 
gland and secreted into saliva and plasma. Similar to glucagon, and perhaps due 
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to increased catecholamines, plasma levels of EGF increase during fasting in 
mice (Grau et al., 1994). Importantly, microsomal studies reveal a decreased 
affinity of EGF for its receptor during fasting (Freidenberg et al., 1986). Early 
studies of EGF reveal its ability to stimulate glycogen synthesis through 
activation of glycogen synthase α (Bosch et al., 1986; Chan and Krebs, 1985). 
This dynamic regulation allows EGFR signaling to mimic insulin-mediated 
suppression of HGP by promoting the uptake and storage of glucose as 
glycogen. For example, like insulin, EGF stimulation suppresses G6Pase and 
PEPCK expression in vitro and in vivo and activates glycogen synthase (Fillat et 
al., 1993; Chan and Krebs, 1985). Moreover, adenoviral-mediated 
overexpression of MEK, a downstream effector of EGFR signaling, decreases 
G6Pase expression and fasting blood glucose in mice (Jiao et al., 2013). 
Furthermore, cell line studies reveal phorbol esters, which activate the MAPK 
cascade through phospholipase C and diacylglycerol generation, suppress 
G6Pase promoter activity, and this suppression is lost via treatment of MEK 
inhibitors (Schmoll et al., 2001). Taken together, the suppression of 
gluconeogenesis and activation of glycogen synthase suggest an anabolic role 
for EGF. These effects may be independent of hepatic EGFR expression as liver 
specific EGFR knockout mice display similar hepatic metabolic function on 
standard chow diets (Natarajan et al., 2007). 
Mig6 and EGFR: Because EGFR signaling activates proliferation, 
migration, differentiation, and cell cycle entry, controlling stimulus duration and 
intensity is vital to avoid uncontrolled growth and mitigate the risk of cancer 
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(Fischer et al., 2003). Therefore, EGFR signaling has many negative feedback 
regulator mechanisms, including receptor endocytosis, phosphatases, and most 
importantly, inducible feedback inhibitors. Physiologically, EGFR signaling 
activates the transcription of several inducible feedback inhibitors, including 
Socs4, Socs5, Lrig1, and Mig6, which serve to shut off EGFR activation and 
signaling in a classical negative feedback manner (Segatto et al., 2011). Socs4, 
Socs5, and Mig6 are transcriptionally activated rapidly (1-4 h) following mitogenic 
signals (Kario et al., 2005; Fiorentino et al., 2000).  
Of all the inducible EGFR negative feedback inhibitors, Mig6 is the only 
one known to be induced by a variety of stress stimuli including hypoxia, 
cytokines, and phorbol esters (Chu et al., 1988; Radaelli et al., 2003; Xu et al., 
2006; Zhang and Vande Woude, 2007). Early studies reveal insulin, cAMP, and 
hydrocortisone induce Mig6 gene transcription (Lee et al., 1985). EGF induces 
Mig6 gene expression directly through EGFR mediated MAP kinase signaling, as 
indicated by inhibitor studies (Fiorini et al., 2002). The Mig6 gene encodes a 53 
kDa protein containing 14-3-3, SH3, CRIB, PDZ, and EGFR binding domains 
(Makkinje et al., 2000). The expression of Mig6 correlates with the transition from 
G1 to S phase in synchronized cells, indicating its importance in cell cycle control 
(Wick et al., 1995). Mutation and crystal structure studies established the 
EGFR/ErbB binding region that contributes to Mig6’s inhibitory function against 
EGFR (Anastasi et al., 2007; Zhang et al., 2007). Thus, Mig6 is subjected to a 
variety of regulation allowing for the precise control of EGFR signaling during 
both physiological and pathophysiological conditions. 
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Mig6 binds to EGFR, thereby preventing its autophosphorylation, while 
enhancing ubiquitin-mediated degradation (Zhang et al., 2007; Frosi et al., 2010). 
Knockdown studies in vitro and gene deletion experiments in vivo reveal Mig6 
deficiency promotes sustained EGFR signaling and enhanced ERK 
phosphorylation; whereas adenoviral-mediated overexpression of Mig6 has the 
opposite effects (Reschke et al., 2010; Colvin et al., 2013).  
Control of Mig6: Mig6 has a short half-life under normal conditions (~1-2 
h) (Fiorini et al., 2002). However, our group has shown protein turnover is slowed 
during stress conditions (here and Chen et al., 2013). Mig6 transcripts also 
evade transcriptional repression during ER stress conditions (Chen et al., 2013). 
In addition, Mig6 is subjected to posttranslational modifications. Recent studies 
indicate Mig6 contains several serine and tyrosine residues susceptible to 
phosphorylation (Liu et al., 2012; Park et al., 2015). These studies suggest Mig6 
itself is subject to regulatory control, indicating the importance of EGFR feedback 
inhibition. 
Mig6 function: As previously mentioned, Mig6 is induced by a variety of 
ligands, including HGF. Suppression of Mig6 via siRNA increases cell migration 
in mouse liver progenitor cells in a HGF/c-Met receptor dependent manor 
(Descot et al., 2009). Mig6 induction by EGFR activation serves to protect cells; 
however, Mig6 induction by cellular stressors leads to apoptosis in a variety of 
cell types (Chen et al., 2013, 2014; Makkinje et al., 2000; Reschke et al., 2010; 
Xu et al., 2005, 2006). Inversely, mic lacking Mig6 have reduced in utero survival 
and die within 6 months of age. Interestingly, these mice are subjected to hyper-
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proliferation of skin, cartilage and bone (Ferby et al., 2006; Jin et al., 2007; 
Zhang et al., 2005). In fact, in our animal facility, out of hundreds of litters only a 
few pups were successfully born (Chen and Lutkewitte, personal 
communication). The increase in proliferative response is attributed to overactive 
EGFR signaling (Ferby et al., 2006). These findings reiterate the importance of 
Mig6 in the regulation of growth.  
In liver, reducing Mig6 with either genetic ablation or siRNA-mediated 
suppression enhances EGFR activation and mitogen signaling (Reschke et al., 
2010). Additionally, hepatocytes lacking Mig6 exhibit increased EGFR signaling 
in vitro and enhanced liver regeneration following partial hepatectomy in vivo 
(Reschke et al., 2010). Mig6 liver-specific knockout (LKO) mice present with 
hepatomegaly and increased serum cholesterols (HDL and LDL) (Ku et al., 
2012). The changes in cholesterol have been attributed to decreases in bile acid 
reuptake, though the exact mechanisms need further exploration.  
Given the array of pathologies associated with NAFLD and the recent links 
between the EGFR feedback inhibitor, Mig6, and hepatic metabolism, we sought 
to define a possible mechanism through which Mig6 affects NAFLD 
development. Because Mig6 is induced by stress, we tested the extent to which 
hepatic EGFR activation was decreased during pharmacological-, fatty acid-, and 
obesity-induced ER stress due to Mig6. We utilized both in vitro and in vivo 
models of substrate-induced hepatic stress and have determined several novel 
mechanisms through which Mig6 regulates hepatic metabolism (Figure 1). 
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Figure 1: Proposed model for Mig6 activation and EGFR inhibition during 
obesity-induced stress 
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AIMS 
Aim 1: Determine the extent to which Mig6 regulates EGFR signaling 
during hepatic ER stress. Given the large precedence of research outlining 
Mig6 as a EGFR regulator that becomes inappropriately activated during stress 
conditions, we hypothesized that fatty-acid induced ER stress activated Mig6 
expression and decreased EGFR activation and cell survival.  
Aim 2: Determine how Mig6 upregulation during obesity and obesity-
induced ER stress alters hepatic metabolism. Several studies reveal 
compromised EGFR activation during obesity-induced hepatic stress. 
Furthermore, initial studies suggest Mig6 and EGF ligand are important 
regulators of hepatic metabolism and function, therefore, we hypothesized high 
fat diet-fed mice will have reduced EGF-mediated EGFR activation, and Mig6 
ablation will have improved hepatic function and metabolism. 
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CHAPTER 2: MATERIALS AND METHODS 
Animal studies 
Control C57Bl/6J mice: All animals were handled and cared for 
according to protocols approved by the Indiana University School of Medicine 
Institutional Animal Care and Use Committee. Mice were weaned at three to four 
weeks of age depending on size, maintained on a standard 12-h light-dark cycle, 
and had free access to chow diet and water. BLKS db mice (heterozygous db/+ 
and homozygous db/db littermates) were maintained by Dr. David Morris from 
the laboratory of Dr. Carmella Evans-Molina under similar conditions as C57Bl/6J 
mice. For initial high fat feeding studies, six-week-old male C57Bl/6J mice were 
fed either breeder chow (15% kcal from fat) or a high fat diet (HFD, 60% kcal 
from fat, no. D12492, Research Diets, New Brunswick, NJ) for 15 weeks. For 
fasting studies, food was removed at 9:00 a.m. for 6 or 5 h (for appropriate test). 
For overnight fasting and refeeding studies, mice were fasted at 5:00 p.m. 
through the following day or refed ab libum the last 6 hours. 
Mig6 liver-specific knockout mice (LKO) and littermate controls: Mig6 
LKO mice were generated from Mig6 homozygous flox mice (Mig6fl/fl) obtained 
from Dr. George Vande Woude and crossed with mice expressing Cre 
recombinase under the control of the albumin promoter (B6.Cg-Tg(Alb-
cre)21Mgn/J, The Jackson Laboratory, Bar Harbor, ME). DNA was extracted 
from tail biopsies and amplified using Extract-N-Amp® (Sigma Aldrich, St. Loius, 
MO), and genotypes were determined as described by Vande Woude (flox 
alelles) and The Jackson Laboratory (Alb-cre); examples are shown in chapter 4. 
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At six weeks of age, Mig6 LKO and littermate controls were fed either a low fat 
diet (LFD, 10% kcal from fat with matched sucrose content of HFD, no. D12492J, 
Research Diets) or HFD (as described above) for 16 weeks. 
Metabolic studies: Blood was collected from tail veins via tail nick, and 
blood glucose was measured using an AlphaTRAK glucometer (Abbott 
Laboratories, Abbott Park, IL). Glucose tolerance tests (GTT) and modified GTT 
were performed on 6 h-fasted mice given an intraperitoneal (IP) bullous injection 
of glucose (2 g/kg bw, Sigma) and blood glucose was measured at times 
indicated. For modified GTT, tail blood (~100 µL) was collected into EGTA 
coated capillary tubes (Sarstedt, Numbrecht Germany) and plasma was 
separated via centrifugation at 6000 rpm for 10 min at 4°C. Plasma was diluted in 
plasma diluent and insulin was measured using an ultra-sensitive mouse insulin 
ELISA (Crystal Chem, Downers Grove, IL). Insulin tolerance tests (ITT) were 
performed on 5 h-fasted high fat fed mice given an IP injection of human 
recombinant insulin (0.75 U/kg bw in 0.01% bovine serum albumin (BSA), 
Novolin U100, Novo Nordisk). To avoid adverse hypoglycemia, if a blood glucose 
fell below 50 mg/dL, then the mouse was given an IP bolus of glucose (2g/kg bw) 
and further analysis was stopped. Pyruvate tolerance tests (PTT) were 
performed on 16 h-fasted high fat fed mice given a IP injection of sodium 
pyruvate (2 g/kg bw, Sigma) dissolved in phosphate-buffered saline (PBS).  
Plasma metabolites: Plasma samples were collected from 16 h-fasted 
mice at the time of termination. Triglycerides and non-esterified free fatty acids 
were measured using colorimetric enzymatic assays (Wako Diagnostics, 
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Richmond, VA). Plasma AST, ALT, albumin, HDL, and LDL were determined by 
the Translation Core of the Center for Diabetes and Metabolic Diseases at 
Indiana University School of Medicine (IUSM). Plasma insulin was measured in 6 
h- and 16-h fasted mice as described above. 
Hepatic assessment 
Immunohistochemistry: Following termination at 15-16 weeks of diet, 
livers were immediately harvested, weighed, and sections of the left lateral lobe 
were removed and placed in zinc formalin for 3 h, then rinsed in 70% ethanol for 
paraffin embedding. The remaining liver was minced and flash frozen in liquid 
nitrogen. Paraffin embedding, sectioning (5 µM), and hematoxylin and eosin 
staining was performed by the IUSM Histology Core. Microscopic examination 
was performed by a board-certified veterinary pathologist (Dr. Abigail Cox 
Durkes, MS, DVM, Diplomate ACVP, Department of Comparative Pathobiology, 
Purdue University College of Veterinary Medicine). The interpretation was based 
on standard histopathological morphology and NAFLD activity scores (NAS, 
(Kleiner et al., 2005)). The pathologist was blinded to the treatment groups. To 
determine the NAS, a semi-quantitative method was used that included 
percentage of hepatic steatosis, hepatic inflammation, and the presence of 
balloon cells indicating hepatocellular injury. A histo-morphological scale is 
provided in Table 1. 
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Table 1: Histological scoring parameters of H&E liver sections 
Item Definition Score 
Steatosis <5% 
5%-33% 
>33%-66% 
>66% 
0 
1 
2 
3 
Lobular inflammation No foci 
<2 foci per 200X field 
2-4 foci per 200x field 
>4 foci per 200x field 
0 
1 
2 
3 
Liver cell injury  
(ballooning: cellular 
enlargement 1.5-2 times the 
normal hepatocyte diameter, 
with rarefied cytoplasm) 
None 
Few balloon cells (rare but 
definite) 
Many cells/prominent ballooning 
0 
1 
 
2 
 
Notes: Ballooning is difficult to assess in mice because their hepatocytes are    
normally variably sized. A score of 1.5 indicates that there were prominent but 
focal aggregates of balloon cells, not diffuse which would warrant a 2. A score of 
2.5 in steatosis indicates that are areas within the section that are a 3 but also 
areas that are a 2. 
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Immunofluorescence: Paraffin-embedded liver sections were de-waxed 
in xylenes and rehydrated by ethanol gradient (100, 90, 80, 70% for 60 seconds 
each). Slides were rinsed in ddiH2O and boiled in antigen unmasking solution 
(Vector Labs, Burlingame, CA) in a microwave over for 13.5 min at 1000 watts. 
Slides were allowed to cool before blocking in blocking solution (Vector Labs) for 
30 min at RT. Primary rabbit anti-phospho-histone H3 (PHH3) antibody (Millipore, 
Billerica, MA) was diluted in antibody diluent (1:200, Vector Labs) and incubated 
overnight at 4°C. Slides were incubated in secondary Alexa Flura 555 for 1 h 
prior to DAPI staining (5 min in DAPI buffer (PBS with 0.3 M NaCl and 0.03 M 
Na+ Citrate) and mounting. Slides were allowed to cure and imaged using a Zeiss 
LSM710 Confocal Microscope. Quantification of PHH3+ cells and nuclei were 
performed on three random 3x3 40X tiles scans using ImageJ software (National 
Institutes of Health).  
Beta cell area: Paraffin-embedded pancreata were dewaxed and 
prepared as before with the exception of incubation in anti-rabbit primary insulin 
antibody overnight at 4ºC. Sections were washed and incubated in peroxidase 
conjugated anti-rabbit IgG for 30 min. Following a wash cycle sections were 
developed with peroxidase substrate for 2 min. The slides were then counter-
stained with Hematoxylin for 10 s before dehydration and mounting. Area was 
quantified using Axion software and determined as area of total pancreas divided 
by insulin positive area. 
Oil Red-O: For frozen sections, livers from the same left lateral lobe as 
above were incubated in 4% paraformaldehyde for 3 h, washed in PBS, and 
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dehydrated in 30% sucrose overnight at 4°C. The following day tissue was rinsed 
in 50% optimal cutting temperature resin (OCT)/sucrose for 30 min prior to 
transfer to 100% OCT and frozen at -80°C until sectioned (8 µm) using a cryostat. 
Frozen sections were thawed, dried, and stained for Oil-Red-O (Sigma) as 
previously described (Mehlem et al., 2013). Briefly, sections were fixed in 
paraformaldehyde (PFA) for 20 min, rinsed in ddiH2O and incubated in freshly 
prepared Oil-Red-O for 5 min. Slides were rinsed in ddiH2O for 30 min, and 
immediately mounted using water soluble mounting media. Ten random 40 X 
bright field images per section were used for quantification using ImageJ 
software.  
Insulin signaling: For insulin signaling studies, mice were fasted 
overnight and IP injected with either vehicle (PBS with 0.01% BSA) or insulin (10 
min, 5 U/kg bw) prior to harvest. Frozen liver samples were placed in lysis buffer 
(100 mg/mL, describe below) containing 2% SDS and homogenized (PolyTron 
PT2100, Kinematica AG, Luzern, Switzerland). Samples were rotated for 30 min 
at 4°C prior to centrifugation. The aqueous layer was removed, and samples 
were centrifuged again prior to western analysis.  
Hepatic triglyceride content: Frozen tissue (100 mg) was homogenized 
in PBS (1 mL) and mixed with a 2:1 mixture of chloroform and methanol (CHCl3). 
Samples were vortexed and mixed on a rocker for 30 min at 4ºC. Aqueous and 
lipid layers were separated by centrifugation (3000 rpm) for 10 min at 4ºC. The 
lower CHCl3 layer was collected and the chloroform was evaporated overnight in 
a fume hood. Lipids were resuspended in isopropanol plus 1% triton-100 by 
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vortexing and heating at 65ºC. Triglycerides were determined using a colorimetric 
enzymatic assay (WAKO). 
Real-time quantitative PCR and RNA sequencing: Frozen tissue was 
lysed in Qiazol® (≤10 mg/mL, Qiagen, Valencia, CA) and homogenized (Polytron 
PT2100). Samples were allowed to rest before extraction by vortexing in 2:1 
chloroform: methanol. Samples were centrifuged and RNA was extracted from 
the aqueous layer using an RNeasy Mini Prep kit (Qiagen). Genomic DNA was 
removed via on column DNA digest (Qiagen).  
For RT-qPCR, complementary DNA was generated using high capacity 
cDNA kit (Applied Biosystems, Foster City, CA). Quantitative PCR was 
performed using Taqman Master Mix and Taqman probes as listed in Table 2. 
RNA content was normalized to GAPDH and expression levels were quantified 
using 2-ΔΔCT method from at least three independent experiments performed in 
triplicate. Complete RNA sequencing studies were performed by the IUSM 
Center for Medical Genomics. Briefly, RNA quality was determined using a 
bioanalyzer (Agilent Technologies, Santa Clara, CA) and sequencing was carried 
out using an Ion Torrent Sequencer (Thermo Fisher).  
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Table 2: List of Taqman Probes for qPCR 
Gene Product number Species 
MIG6 Hs0021960_ml Human 
CHOP Hs00358796_gl Human 
BIP/HSP5A Hs00607129_gh Human 
SOCS4 Hs00328404_s1 Human 
SOCS5 Hs00751962_s1 Human 
LRIG1 Hs00394267_m1 Human 
GAPDH Hs02758991_g1 Human 
mig6 Rn01520745_m1 Rat 
chop Rn01458526_m1 Rat 
bip/hsp5a Rn01435769_g1 Rat 
socs4 Rn01414734_m1 Rat 
socs5 Rn01769079_m1 Rat 
lrig1 Rn01421201_m1 Rat 
gapdh 4352338E Rat 
egfr Mm00433023_m1 Mouse 
mig6 Mm00505292_m1 Mouse 
gapdh 4351309 Mouse 
pepck Mm00440636_m1 Mouse 
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Table 3: List of primers for SYBR green qPCR 
Gene 5’-3’ Species 
g6pase 
Fw-CCATGCAAAGGACTAGGAACAA 
Rev-TACCAGGGCCGATGTCAAC 
Mouse 
glucokinase 
Fw-CCCTGAGTGGCTTACAGTTC 
Rev-ACGGATGTGAGTGTTGAAGC 
Mouse 
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Cell culture 
Cell lines: Cell lines were purchased directly from ATCC (Manassas, VA). 
HepG2 human, male, hepatocellular carcinoma cells (HB-8065, ATCC) were 
cultured in DMEM containing 25 mM glucose supplemented with 10% fetal 
bovine serum (FBS; Sigma Aldrich, St. Louis, MO), 1 mM sodium pyruvate, and 
penicillin-streptomycin (100 U/mL). H4IIE rat hepatoma (CRL-1548, ATCC) were 
cultured similar to HepG2 cells with the exception of the DMEM contained 5.5 
mM glucose. Cell lines were regularly passaged and seeded at appropriate 
confluence for studies. 
Primary hepatocytes: Primary hepatocytes were isolated from Sprague 
Dawley rats at Triangle Research Labs (Durham, NC) and shipped the following 
day; upon arrival, shipping media was replaced with DMEM containing 25 mM 
glucose and supplemented as above (both dexamethasone and insulin are 
known to induce Mig6 gene expression and were therefore omitted during 
palmitate treatments (Chu et al., 1988; Colvin et al., 2013)). 
Ligand stimulation and drug treatments: Sixteen hours prior to ligand 
stimulation and during stress treatments, FBS-containing media was replaced 
with media containing 0.1% bovine serum albumin (BSA, Sigma Aldrich). Cells at 
70-80% confluency were treated with thapsigargin (Sigma Aldrich), tunicamycin 
(Sigma Aldrich), or vehicle (DMSO) as indicated. Cells were treated at dose and 
time indicated with palmitate or vehicle (BSA) using sodium palmitate (Sigma 
Aldrich) dissolved in 70% ethanol and conjugated at 7:1 ratio to BSA. Hydrogen 
peroxide (Sigma Aldrich) treatments were performed with freshly diluted H2O2 in 
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serum free media for times and doses indicated. Cells were stimulated with 50 
ng/mL recombinant rat EGF in 0.01% BSA (R&D systems, Minneapolis, MN) for 
times indicated.  
Western blot analysis and antibodies: HepG2, H4IIE, and primary rat 
hepatocytes were washed twice with ice cold PBS and lysed in IGEPAL lysis 
buffer (10% IGEPAL, 10% glycerol, 1 mM NaCl, 1 mM HEPES, and O-octyl 
glucoside, phosphatase and protease inhibitor tablets (Roche, Mannheim, 
Germany). Samples were vortexed and centrifuged at >20,000 x g for 10 min at 
4°C. SDS (2%) was added to lysates from cells treated with palmitate, then 
sonicated and spun at room temperature. The middle aqueous layer was 
removed and re-centrifuged. Protein content was determined by bicinchoninic 
acid assay (ThermoFisher) and read on a spectrometer (SpectrMax M5, 
Molecular Devices, Sunnyvale, CA). Protein (30-40 g) was reduced in LDS 
loading buffer plus reducing agent (Invitrogen) and boiled at 100°C for 6 min. 
Samples were loaded onto 10% Bolt Bis-Tris gels (Invitrogen) and separated at 
140 volts for 50 min. Proteins were transferred to an Immunobilon-FL Transfer 
Membrane (Millipore, Bedford, MA) at 110 volts for 50 min in ice cold transfer 
buffer. Membranes were blocked in Li-Cor Odyssey blocking buffer for 1 h at 
room temperature and incubated with primary antibody overnight. Membranes 
were then washed 3 times in TBS and incubated with IRDye 800 or 700 
flurophore-labeled secondary antibodies for 1 h. Antibodies were diluted in either 
1% w/v polyvinylpyrrolidone or signal enhancer (Nacalai, San Diego, CA) and are 
listed in Table 4. Blots were washed in TBS-1% Tween and protein bands were 
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visualized on the Odyssey System (LI-COR) and quantified using ImageJ 
software. Boxes around the representative images indicate antibodies probed on 
the same membrane.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: List of antibodies used 
Antibody Manufacturer Product Dilution 
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Number 
Mig6 Santa Cruz Biotechnology  137154 1:500 
P-eif2α Cell signaling 3398 1:1000 
eif2α Cell signaling 5324 1:1000 
P-ERK 1/2 Cell signaling 9101S 1:1000 
ERK 1/2 Cell signaling 4696S 1:1000 
P-EGFR Cell signaling 3777S 1:1000 
EGFR Cell signaling 4267S 1:1000 
Caspase 3 Cell signaling 9662 1:1000 
JNK Cell signaling 9252S 1:1000 
P-JNK Cell signaling 9251S 1:1000 
Actin MP biomedical 691002 1:10000 
GAPDH Abcam 9484 1:2000 
γ-tubulin Sigma Aldrich (mouse) T6557 1:1000 
EGFR Sigma Aldrich (mouse) E3138 1:1000 
FLAG Sigma Aldrich (mouse) F3165 1:1000 
Insulin Santa Cruz Biotechnology Sc9168 1:500 
Phosphohistone H3 Millipore 06-570 1:200 
G6Pase Santa Cruz Biotechnology Sc2584 1:500 
P-AKT Cell signaling 4058S 1:1000 
AKT Cell signaling 2920S 1:1000 
p-foxo1 Cell signaling 9461S 1:1000 
Foxo1 Abcam ab131206 1:2000 
 
 
 
 
 
 
Reverse transcription and quantitative PCR: For RNA isolations, cells 
were lysed in RLT buffer containing 1% -mercaptoethanol. Genomic DNA was 
removed via gDNA column (Qiagen, Valencia, CA), and RNA was isolated with 
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an RNeasy mini prep kit (Qiagen). Complementary DNA was generated using 
high capacity cDNA kit (Applied Biosystems, Foster City, CA). Quantitative PCR 
was performed using Taqman Master Mix and Taqman probes as listed in Table 
2. Gene expression was also carried out using SYBR Green Taqman gene 
expression system with primer sets listed in Table 3. RNA content was 
normalized to GAPDH or actin and expression levels were quantified using 2-ΔΔCT 
method from at least three independent experiments performed in triplicate. 
Mig6 overexpression and siRNA transfection: For gene overexpression 
studies, cells were transduced with adenoviral vectors driving the expression of 
green florescence protein (GFP) or Mig6 under the control of the cytomegalovirus 
(CMV) promoter for 24 h as previously described (Xu et al., 2005). Media was 
replaced with complete media the follow day and ligand stimulation was 
conducted 48 h after transduction. For RNA interference studies, cells were 
seeded at 50% confluency and forward transfected with siRNAs (30 pmol) using 
Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA) according to manufacturer’s 
guidelines. Sequences for RNAi were purchased as duplexes from Invitrogen 
and are as follows: Mig6-1 forward 5’-CGAUAAUAGAACUAGUGACtt-3’ reverse 
5’-GUCACUAGUUCUAUUAUGtt-3’, Mig6-2 forward 5’-
GCUAUGUGUCUGACCAAAAtt-3’ reverse 5’-UUUUGGUCAGACAUAGCtg-3’, 
and the control GL-2 siRNA forward 5’-CGUACGCGGAAUACUUCGAtt-3’ 
reverse 5’-UCGAAGUAUUCCGCGUACGtt-3’ as previously described (Reschke 
et al., 2010). The following day the media was replaced with complete media. 
Ligand and drug treatments were conducted as previously described.  
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Caspase 3/7 activity assay: HepG2 cells were transfected as before and 
the following day trypsinized and plated at 40,000 cells per well in black-walled 
96-well plates. The following day media was removed and replaced with serum 
free media containing 0.1% BSA and treated with vehicle (BSA) or palmitate for 8 
h. Following palmitate treatment, caspase 3/7 activity was measured using 
ApoLive-Glo Multiplex Assay (Promega, Madison, WI). Briefly, cells were 
incubated with Caspase-Glo 3/7 reagent for 30 min and luminescence was 
measured using a SpectrMax M5 (Molecular Devices, Sunnyvale, CA). Relative 
luminescence units were normalized to siCon untreated cells and are given as 
fold increase in caspase 3/7 activity. 
Statistical analysis: Experiments were performed at least three 
independent times. Significance was determined by one- or two-tailed Student’s 
t-test or one- or two-way ANOVA with Bonferroni multiple comparison tests 
where appropriate. Differences were considered significant when P < 0.05. Data 
are reported as means ± SEM. 
 
CHAPTER 3: RESULTS 
Mig6 decreases hepatic EGFR activation and survival during saturated fatty 
acid-induced endoplasmic reticulum stress. 
Synopsis: Hyperlipidemia associated with obesity and T2DM promotes 
excess hepatic lipid storage (steatosis) and ER stress, thereby reducing hepatic 
cell proliferation and survival. An important receptor tyrosine kinase controlling 
liver proliferation and survival is EGFR. EGFR expression and activation are 
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decreased during steatosis in humans and several animal models of obesity. 
Therefore, restoring EGFR activation in obesity-induced ER stress and diabetes 
could restore the liver’s capacity for survival and regeneration. As an inducible 
feedback inhibitor of EGFR activity, mitogen-inducible gene 6 (Mig6) is a novel 
target for enhancing EGFR signaling during diet-induced obesity (DIO) and T2D. 
Thus, we hypothesized hepatic ER stress induces Mig6 expression and 
decreases EGFR activation. We discovered that both pharmacological- and fatty 
acid-driven ER stress increased Mig6 expression and decreased EGF-mediated 
EGFR activation in primary rat hepatocytes and cell lines. Furthermore, siRNA-
mediated Mig6 knockdown restored EGFR signaling and reduced caspase 3/7 
activation during ER stress. Therefore, we conclude Mig6 is increased during ER 
stress in DIO, thereby reducing EGFR activation and enhancing cell death. The 
implications are the induction of Mig6 during DIO and diabetes may decrease 
hepatocyte survival, thus hindering cellular repair and regenerative mechanisms. 
Introduction: ER stress contributes to the pathogenesis of obesity and 
diabetes (Oyadomari et al., 2008; Ozcan et al., 2004; Puri et al., 2008). A major 
contributor to ER stress in hepatocytes is increased saturated FFA delivered to 
the liver during chronic over nutrition (Pfaffenbach et al., 2010). The induction of 
chronic ER stress in hepatocytes is associated with increased lipogenesis, insulin 
resistance, and chronic inflammation (Hirosumi et al., 2002; Gao et al., 2004; 
Oyadomari et al., 2008). These pathologies are associated with increased 
NAFLD progression in liver. In fact, severe hepatic ER stress may cause 
progression towards NASH and eventual liver failure. Therefore, improving 
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cellular survival pathways would likely improve the overall pathogenesis of 
NAFLD.  
The insulin receptor is a RTK critical to maintaining hepatic metabolism 
and its activity is decreased during NAFLD (Ozcan et al., 2004). In addition to the 
insulin receptor, EGFR is a master regulatory of both survival and metabolism. 
As previously mentioned, EGFR signaling is pro-growth, and pro-survival through 
the induction of pro-survival factors including bcl-2 and survivin and the inhibition 
of cellular caspase 3/7 activity (Paranjpe et al., 2010; Schiffer et al., 2005). 
Notably, chemical chaperons, which alleviate fatty acid induced ER stress 
improve cell survival. However, the exact mechanisms of how ER stress 
response impacts survival signaling remain unknown. In β-cells, ER stress 
induces the EGFR inhibitor, Mig6, and exacerbates cell death during chemical 
stress and Mig6 ablation improves survival. In liver, Mig6 knockdown, enhances 
EGFR signaling and cell cycle progression (Reschke et al., 2010). As the liver 
progresses from simple steatosis towards NASH, the regeneration capacity in 
conjunction with EGFR activation and expression are decreased (Collin de 
l’Hortet et al., 2014). 
Therefore, we sought to determine the relative contributions of Mig6 
during fatty-acid induced hepatic ER stress. Here we utilized several cellular 
modes of ER stress to show reduced EGFR activation under ER stress. 
Furthermore, ER stress induced Mig6 expression and enhance protein stability. 
Mig6 ablation using siRNAs restored EGFR signaling and reduced caspase 3/7 
activity following palmitate treatment. These data suggest that Mig6 plays an 
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inhibitory role during ER stress and could possible serve as a target for improving 
cellular survival during fatty-acid induced cell stress. 
Results 
Palmitate and ER stress decrease EGFR activation and activates 
Mig6 expression: We have previously determined that cellular stress induces 
Mig6, which impairs EGFR signaling and promotes apoptosis in pancreatic β-
cells (Chen et al., 2013). To determine if EGFR is also inhibited by fatty acid-
induced ER stress, primary hepatocytes were treated with the saturated fatty acid 
palmitate prior to EGF stimulation. Indeed, palmitate treatment decreased EGF-
mediated EGFR activation and prevented the induction of downstream ERK 
phosphorylation (Figure 2A-C). This signaling inhibition occurred in the context of 
increased intrinsic cell death as measured by caspase 3/7 activity (Figure 2D).  
The magnitude and duration of EGFR signaling can be modulated by 
several inducible feedback inhibitors, including Socs4, Socs5, Lrig1, and Mig6. 
Thus, inhibitor expression levels were assessed in palmitate-treated H4IIE cells. 
Under these ER stress conditions with elevated levels of Bip and Chop, only 
Mig6 gene expression was significantly increased whereas the other inhibitors 
were not induced (Figure 3). 
Diet-induced obesity triggers a variety of pathological responses in the 
liver including inflammation, insulin resistance, steatosis, and ER stress 
(Hotamisligil, 2010b; Ozcan et al., 2004). Because we have previously 
established that Mig6 is upregulated during ER stress in non-hepatic tissues 
(Chen et al., 2013), we sought to directly measure the effects of chemically-
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induced ER stress on EGFR inhibitors in hepatocytes, with the rationale being 
that ER stress in response to palmitate treatment promotes Mig6 induction. H4IIE 
cells were treated with the ER stress inducer thapsigargin, which inhibits the 
sarcoendoplasmic reticulum calcium transport ATPase, and ER stress was 
confirmed by elevated Bip and Chop expression (Figure 4A,B). Like palmitate 
exposure, thapsigargin treatment increased Mig6 gene expression in both dose-
responsive and time-dependent manners (Figure 4C). Further, ER stress, as 
indicated by elevated Bip expression, increases Mig6 transcript and protein 
levels in human HepG2 cells (Figure 5). Importantly, no changes were observed 
in Socs4, Socs5, and Lrig1 gene expression in H4IIE during thapsigargin 
treatment compared with DMSO, and only Socs4 gene expression was increased 
during thapsigargin treatment in HepG2 cells (Figure 6). Thus, Mig6 alone 
appears to be the primary form of negative feedback inhibition of EGFR in 
hepatocytes during ER stress.  
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Figure 2: Palmitate decreases EGFR activation in primary hepatocytes and 
activates caspase 3/7. 
Primary rat hepatocytes were treated with BSA or palmitate (750 μM) for 48 h. 
Twenty-four h prior to rrEGF (50ng/mL) media was replaced with serum free 
media. EGFR and ERK activation were assessed by Western blot. Shown is a 
representative blot (A). P-EGFR and P-ERK were normalized to EGFR and ERK, 
respectively (B,C). Caspase 3/7 activity was measured by luminescence 
following palmitate treatment for 48 h (D). Data are reported as means ± SEM; n 
= 3-4. *, p < 0.05 vs. untreated cells; †, p < 0.05 vs. BSA treated cells.  
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Figure 3: Palmitate-induced ER stress increases Mig6 expression in H4IIE 
cells. 
H4IIE cells were treated with vehicle (BSA) or palmitate for 8 h at doses indicated 
in serum free media. mRNA expression was determined by qPCR. ER stress 
was confirmed by Bip and Chop mRNA expression (A,B). Mig6, Lrig1, Socs4, 
and Socs5 mRNA were also determined (C-F). Data are reported as means ± 
SEM; n = 4. *, p < 0.05 vs. DMSO. 
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Figure 4: ER stress induces Mig6 in rat H4IIE cells. 
H4IIE cells were treated with vehicle (DMSO) or 1.0 µM thapsigargin (Tg) for 6 h 
or dose (nM) and time (h) indicated. Mig6, Chop and Bip mRNA (A-C) expression 
were assessed by qPCR. Data are reported as means ± SEM; n = 4. *, p < 0.05 
vs. DMSO. 
49 
 
Figure 5: ER stress induces Mig6 in HepG2 cells. 
HepG2 cells were treated with vehicle (DMSO), 1.0 µM thapsigargin (Tg), or 1.0 
µM tunicamycin for hours (h) indicated. Bip and Mig6 mRNA (A-D) expression 
were assessed by qPCR. Mig6, P-eif2α, and eif2α protein expression were 
determined by Western blot. Shown is a representative blot (E). Mig6 was 
normalized to actin (F). Data are reported as means ± SEM; n = 4. *, p < 0.05 vs. 
DMSO. 
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Figure 6: ER stress does not activate EGFR inhibitors in cell lines. 
H4IIE cells were treated with vehicle (DMSO) or thapsigargin (1 μM) and 
tunicamycin (1 μM) for 6 h in serum free media. Lrig1, Socs4, and Socs5 mRNA 
was assessed by qPCR in H4IIE cells (A-C) and HepG2 cells (D-F). Data are 
reported as means ± SEM; n = 4. *, p < 0.05 vs. DMSO. 
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ER stress decreases EGFR activation and stabilizes Mig6 
expression: In agreement with a previous report (Xu et al., 2005) , adenoviral-
mediated flag-tagged Mig6 overexpression is sufficient to decrease EGF-
mediated EGFR activation as measured by phosphorylation of EGFRY1068 at 5 
min compared with controls (Figure 7A,B). Additionally, Mig6 overexpression 
reduced phosphorylation of the downstream kinase ERK1/2 (Figure 7A,C). 
Interestingly, under these conditions in both human and rat cell lines, EGF does 
not induce AKTT308 phosphorylation (Lutkewitte, personal note). Given that 
maximal activation of the EGFR signaling cascade occurred at 5 min post-EGF 
stimulation, this time point was used in subsequent in vitro studies.  
As Mig6 is induced during ER stress and Mig6 overexpression decreases 
EGFR activity, we hypothesized that EGFR activity is decreased during 
chemically-induced ER stress. Again, we used thapsigargin to induce hepatic ER 
stress in HepG2 cells (Figure 8). During this stress condition, EGF-mediated 
EGFR activation is markedly attenuated and apoptosis is activated, as indicated 
by the presence of activated, cleaved caspase 3 on the immunoblot (Figure 8A-
C). Under similar ER stress conditions, we used the flag-tagged Mig6 adenovirus 
to show mig6 stability was markedly increased indicating Mig6 is stabilized during 
ER stress conditions (Figure 8D-E). 
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Figure 7: Mig6 overexpression reduces EGF-stimulated EGFR and ERK 
phosphorylation. 
HepG2 cells were transduced with control GFP- or Mig6-overexpressing 
adenoviruses. After 24 h, media was replaced with serum free media, and the 
following day cells were treated with vehicle or rrEGF (50 ng/mL) for times 
indicated. Shown is representative Western blot (A). p-EGFR and EGFR were 
normalized to tubulin, and P-ERK was normalized to ERK protein, then quantified 
(B,C). Data are expressed as means ± SEM; n = 4. *, p < 0.05 vs. cmv-GFP. 
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Figure 8: Thapsigargin decreases EGFR activation, induces caspase 3 
activation, and stabilizes Mig6 protein expression. 
HepG2 cells were treated with vehicle (DMSO) or thapsigargin (1 μM) for 24 h in 
serum free media prior to rrEGF (50ng/mL) stimulation as indicated (A-C). 
HepG2 cells were transduced with control GFP- or Mig6-overexpressing 
adenoviruses. After 24 h media was replaced with serum free media and treated 
as above (D,E). EGFR activation, caspase 3 cleavage, and flag expression were 
assessed by Western blot. Shown are representative blots (A&D). P-EGFR and 
EGFR were normalized to tubulin then quantified (B, C). Flag-tagged Mig6 
expression was normalized to tubulin and quantified (E). Data are reported as 
means ± SEM; n = 3 (A-C) and n =4 (D,E) *, p < 0.05 vs. DMSO. 
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Mig6 knockdown enhances EGFR activation and reduces caspase 
3/7 activity during ER stress: To establish that the suppression of EGFR 
activation during ER stress is mediated by Mig6, HepG2 cells were pre-
transfected with siRNAs directed against Mig6 (siMig6) or a scrambled control 
siRNA (siCon) and then exposed to thapsigargin (or vehicle) prior to ligand 
stimulation (Figure 9). Compared to siCon-transfected cells, siMig6-transfected 
cells have reduced Mig6 expression and increased EGFR phosphorylation during 
both control (i.e., vehicle-treated) and ER stress conditions (Figure 9A,B). This 
observation confirms Mig6 directly inhibits EGFR activation during ER stress. To 
determine the functional significance of decreased EGFR signaling during ER 
stress, HepG2 cells were treated with palmitate following siRNA-mediated 
suppression of Mig6. Palmitate induced both ER stress and Mig6 transcript 
expression (Figure 10A,B). Mig6 suppression reduced caspase 3/7 activity during 
palmitate treatment compared to siControl-transfected cells (Figure 10C). These 
data indicate Mig6 knockdown restores EGFR signaling leading to reduced 
caspase 3/7 activation and enhanced survival in HepG2 cells during ER stress. 
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Figure 9: Mig6 ablation rescues EGFR activation during ER stress. 
HepG2 cells were pretreated with siRNAs directed against control (siCon), or 
Mig6 (siMig6) for 48 h prior to ligand stimulation. Media was replaced with serum 
free media and either vehicle (DMSO) or thapsigargin (1.0 µM) 16 h prior to EGF 
stimulation (50ng/mL for 5 min). EGFR activation and Mig6 expression were 
determined by Western blot. A representative blot is shown (A). P-EGFR was 
normalized to total EGFR (B). Data are reported as means ± SEM; n = 3. * p < 
0.05 vs. siControl. 
 
 
 
56 
 
Figure 10: Mig6 knockdown during palmitate-induced ER stress decreases 
caspase 3/7 activity in HepG2 cells. 
HepG2 cells were incubated in serum free media containing either BSA or 
palmitate (750 uM) for 8 h. For caspase 3/7 activity cells were treated with 
nothing or oligos directed against control or Mig6 for 48 h. Following transfection, 
media was replaced and cells were treated as before. Caspase 3/7 activity was 
measured using chemiluminescence. Chop and Mig6 mRNA were measured by 
qPCR (A,B) and caspase 3/7 activity is expressed as fold increased 
luminescence from control non-treated cells (C). Data are reported as means ± 
SEM; n=3 p < 0.05 vs. palmitate treated siControl. 
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Discussion: Hyperlipidemia from over-nutrition and obesity increases 
hepatic lipid uptake and deposition (i.e., steatosis). Clinically, steatosis is often 
considered benign, requiring a “second hit” to initiate the necroinflammation and 
steatohepatitis-like lesions responsible for reduced patient survival during the 
transition from simple steatosis to non-alcoholic steatohepatitis (NASH) and 
cirrhosis (Adams et al., 2005; Teli et al., 1995). Hepatic necroinflammation and 
steatohepatitis provoke oxidative stress-induced DNA damage and caspase 
activation (Feldstein et al., 2003; Wieckowska et al., 2006). In response to these 
insults, hepatocytes and local immune cell populations trigger potent activators of 
hepatic DNA damage repair and synthesis, including EGFR, c-Met/HGF receptor, 
and TGF-β receptor and their ligands. These mitogens and their cognate 
receptors have been extensively investigated in healthy livers (Fausto et al., 
2006b; Michalopoulos, 2007, 2010). However, the molecular mechanisms 
responsible for their inhibition during obesity- and ER stress, which compromises 
cell survival, still warrant further exploration. 
One possible explanation for compromised hepatic survival in obesity 
could be stress-mediated feedback inhibition of RTKs. Because obesity and 
impaired insulin signaling cause hepatic ER stress, we also employed ER 
stressors to inhibit EGFR signaling and induce Mig6 expression in hepatocytes. 
The increased Mig6 expression was necessary for inhibiting EGFR activation, as 
evidenced by rescued EGFR activation following Mig6 suppression during stress 
conditions. We speculate Mig6 protein stability may be enhanced during stress 
based on our in vitro studies (Figure 8). Similar to diet-induced EGFR 
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inactivation, previous studies have revealed hepatic steatosis decreased EGFR 
expression and activation in ob/ob (i.e., leptin-deficient) mice (Collin de l’Hortet et 
al., 2014; Gonzalez et al., 2010). Although the exact mechanisms remain elusive, 
EGFR expression can be restored with growth hormone administration in ob/ob 
mice (Collin de l’Hortet et al., 2014). Moreover, leptin administration to ob/ob 
mice fails to rescue the regeneration response following partial hepatectomy, 
suggesting that fatty-liver pathologies might dampen the regenerative response 
through EGFR inactivation (Leclercq et al., 2006). More importantly, these 
studies did not explore the potential contribution from endogenous feedback 
inhibitors such as Mig6. 
EGFR activation is tightly controlled by both receptor-mediated 
endocytosis and ligand-activated feedback inhibition (Segatto et al., 2011). 
Though several endogenous inhibitors exist, few have been examined during 
cellular stress conditions such as ER stress. Here, we demonstrate the largely 
exclusive upregulation of Mig6 during ER stress in liver. Additionally, there was a 
small but significant decrease in lrig1 mRNA expression during thapsigargin-
induced ER stress in rat hepatoma cells. Unlike lrig1, socs4, and socs5, Mig6 
inhibits both receptor activation and enhances receptor degradation (Segatto et 
al., 2011). Therefore, expression of EGFR and its ligands alone may not be 
capable of enhancing proliferation and survival during the mitogenic phase of 
regeneration if its activation is impaired by Mig6 (Ying et al., 2010; Zhang et al., 
2007). During feedback inhibition, Mig6 binds to the catalytic domain of EGFR 
through its ERB binding domain, acting as a docking site for endocytic proteins 
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(Ying et al., 2010; Zhang et al., 2007). ER stress may potentially facilitate this 
binding interaction. However, increased binding of Mig6 to EGFR during stress 
remains to be demonstrated.  
Obesity-induced ER stress causes decreased regeneration following 
partial hepatectomy (Wang et al., 2006b). Conversely, administration of the 
chemical chaperone tauroursodeoxycholic acid alleviates ER stress and restores 
hepatic regeneration in rats (Mosbah et al., 2010). Given that ER stress induces 
Mig6 and Mig6 halts cell cycle progression from G1 to S phase, Mig6 could 
potentially inhibit proliferation during ER stress. For example, proliferation 
requires massive ER expansion and protein translation. If sufficient stress on the 
ER persists, intrinsic mitogen inhibitors may become activated to halt proliferation 
until stress is resolved or the cell undergoes regulated apoptosis. Mig6 
expression enhances apoptosis in several cell types (Makkinje et al., 2000; Xu et 
al., 2005; Chen et al., 2013). Importantly, active proliferation is observed in both 
non-fulminant and fulminant hepatitis, indicating proliferative response alone is 
not sufficient to prevent cell death (Kawakita et al., 1992; Wolf and 
Michalopoulos, 1992). Here, we have demonstrated Mig6 knockdown reduces 
apoptosis through decreased caspase 3/7 activity. Importantly, Mig6 is 
sufficiently upregulated and Mig6 mRNA and protein stability are enhanced 
during ER stress (here and Chen et al., 2013). It will be important to ultimately 
elucidate the extent to which Mig6 mediates the impaired hepatic regeneration 
during obesity and if this occurs through enhanced cell death, decreased 
proliferation, or both. 
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Mig6 could potentially halt the proliferative response of a steatotic liver 
following a hepatectomy. Mig6 ablation permits enhanced hepatic regeneration 
through heightened EGFR activation and signaling (Reschke et al., 2010). 
Additionally, under normal conditions, liver-specific deletion of Mig6 leads to 
hepatomegaly, without any reports of hepatic dysfunction or hepatocellular 
carcinoma development, suggesting Mig6 restricts liver proliferation (Ku et al., 
2012). Physiologically, EGFR controls the initial stages of regeneration when 
hepatocytes are in the first round of the cell cycle. EGFR activation leads to 
downstream kinase cascades including ERK1/2 activation and subsequent 
induction of cyclins, allowing the transition between G1 and S phase of the cell 
cycle (Collin de l’Hortet et al., 2012; Natarajan et al., 2007). Thus, Mig6 inhibits 
the G1 to S phase transition (Colvin et al., 2013). Although the regenerative 
response is subjected to several mitogen receptors, deletion of individual 
receptors, or their ligands, only delays or impairs regeneration without complete 
abrogation. Challenged by obesity-induced ER stress the liver loses the ability to 
fully regenerate following partial hepatectomy suggesting further mechanisms 
remain.  
Here, we describe a mechanism where EGFR is inhibited during ER 
stress, and we speculate that other pro-survival signaling axes like HGF/c-met 
may also be compromised during ER stress. We believe unrestrained EGFR 
signaling in the context of impaired repair and proliferation (e.g., impaired 
regeneration during diet-induced obesity) may accelerate growth and recovery of 
otherwise impaired tissue. Future studies using mice lacking Mig6 in the liver 
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may provide insight into the complete impact of EGFR signaling inhibition during 
regeneration, survival, and repair.  
 
 
 
 
 
 
 
 
 
 
 
 
 
62 
CHAPTER 4: RESULTS 
EGFR activation is decreased and mig6 protein expression is  
increased during obesity in mice. 
Synopsis: Several available animal models exist for the study of NAFLD 
in rodents. Here we utilized samples from 60% HFD fed mice to demonstrate the 
induction of Mig6 during obesity-induced prediabetes (Figure 11). In addition to 
diet-induced models, liver samples from db/db mice were used to assess the 
expression of Mig6 during a condition of reduced EGFR expression and 
signaling. Surprisingly, EGFR expression and activation were decreased and 
Mig6 gene expression was decreased in db/db liver samples compared to their 
control littermates. Next, we determined that hepatic EGFR activation and 
downstream signaling could be acutely activated in vivo and that this signaling 
axis may be compromised during diet-induced obesity in mice. Lastly, utilizing 
Mig6 liver-specific knockout mice we determined Mig6 function during NAFLD. 
Mig6 LKO mice develop hepatomegaly and improved ERK activation in the 
presence and absence of ligand. Furthermore, during HFD, Mig6 LKO mice 
display improved glucose tolerance compared to littermate controls. These 
findings indicated Mig6 may regulated hepatic metabolism during metabolic 
stress. 
Introduction: Several models of obesity-induced NAFLD are well defined 
in mice. Much earlier work utilized leptin deficient models (ob/ob and db/db) that 
develop gross hepatic steatosis and frank diabetes (Anstee and Goldin, 2006). In 
addition, many other genetic mouse models develop NAFLD, including mice 
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lacking ppara, mtp, and cd36 as well as pepck/nsrebp-1a double knockouts 
(Anstee and Goldin, 2006). However, many of these models do not develop 
NASH without a secondary insult. Perhaps the most utilized mouse model of 
NAFLD to NASH progression is the methionine choline deficient (MCD) diet. The 
MCD diet causes impairments in β-oxidation leading to ROS production, 
mitochondrial DNA damage, and apoptotic cell death (Gao et al., 2004). 
However, this diet induces weight loss, low plasma TG, and most critically, near 
normal insulin tolerance with dissimilar lipid distribution patterns than human 
patient samples (Rinella and Green, 2004). 
Most importantly though, ER stress activation, oxidative stress, and 
inflammation are all noted in the progression of NAFLD to NASH. Therefore, we 
sought to test several models that activate stress and NAFLD in mice. As 
previously mentioned, the pro-growth, pro-survival EGFR signaling pathway is 
decreased in genetic models of obesity. In addition to the survival functions of 
EGFR, a novel role in metabolism is recently (re)emerging. EGF function as a 
metabolic regulator were first described in regulation of fasting by Grau et al. in 
1995. Recently, EGFR inhibition is associated with improvements in glucose 
tolerance and insulin action in HFD fed mice (Prada et al., 2009). Conflicting 
studies have shown EGFR activation suppresses G6Pase gene and protein 
expression (Onuma et al., 2009). EGFR signals primarily through the MAPK 
pathway, and the role of MAPK signaling in metabolic regulation are well defined. 
There are four main signaling pathways: ERK1/2, ERK5, p38, and JNK. The role 
of JNK in metabolic regulation is well defined and described above. The p38 
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kinases have also been well defined in feeding/fasting regulation through 
transcriptional control of PGC-1α (Cao et al., 2005). However, the role of ERK1/2 
in metabolic regulation is still poorly understood. Canonical ERK1/2 signaling 
regulates protein synthesis and DNA replication machinery. The ERK isoforms 
are activated by similar stimuli, however ERK2 knockout mice die in utero 
whereas ERK1 mice are viable, suggesting different functions. ERK1 knockout 
mice are protected from diet-induced obesity and have increased insulin 
sensitivity (Bost et al., 2005). These mice have reduced adipogenesis with 
increased energy expenditure. However, the hepatic role of ERK activity remains 
unclear. Recent groups have reported chemical inhibition of ERK activity 
improves insulin resistance in ob/ob mice (Banks et al., 2015). However, the role 
of chronic ERK activity in hepatic metabolism still remains elusive. For example, 
hepatic ERK1/2 activity is induced in both ob/ob and diet-induced mouse models 
(Jiao et al., 2013). Furthermore, hepatic ERK1/2 activity is dynamically regulated 
during fasting conditions and may regulate genes involved in both hepatic 
lipogenesis and gluconeogenesis (Gehart et al., 2010). Others have suggested 
ERK1/2 may exert this activity through the ability to phosphorylate FOXO1 
transcription factors (Asada et al., 2007). Interestingly, a study using a 
recombinant adenovirus expressing a constitutively active form of ERK 
demonstrated improved glucose tolerance through the activation of beta cell 
expansion through a pancreatic-liver-neuronal network (Imai et al., 2008). 
Undoubtedly, EGFR signaling and ERK1/2 activity affect hepatic 
metabolism. However, these studies completely ignore the endogenous feedback 
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inhibitors that regulate the EGFR signaling duration and intensity. Recently, 
hepatic Mig6 expression was implicated in cholesterol metabolism through 
modifications in bile acid synthesis. However, the role of Mig6 in hepatic glucose 
metabolism as well as cellular repair during obesity-induced stress remains 
undefined. Therefore, we sought to determine the most appropriate in vivo model 
to examine the effects of hepatic Mig6 knockout during obesity-induced stress 
conditions. The initial studies are outlined in the next chapter. 
Results 
 Mig6 protein expression is elevated during obesity: Because diet-
induced obesity drives hepatic ER stress, we sought to determine the impact of 
diet-induced obesity on hepatic Mig6 expression. Male C57Bl/6J mice were fed 
diets containing either 15 or 60% kcals from fat for 15 weeks. As expected, HFD-
fed mice had increased body weight and pre-diabetic hyperglycemia and 
hyperinsulinemia compared to LFD-fed controls (Figure 11A-C). Importantly, 
hepatic Mig6 protein expression but not mRNA expression was increased in 
HFD-fed animals compared to LFD-fed controls (Figure 11D-F). 
66 
 
Figure 11: Mig6 is increased in diet-induced obesity and prediabetes. 
Eight-week-old male C57Bl/6 mice (n=4) were fed a LFD (15% calories from fat) 
vs. HFD (60% calories from fat) for 15 weeks. HFD mice develop higher blood 
glucose (A), plasma insulin levels (B), and body weight (C) compared to LFD 
mice. Representative Western blots of liver tissue for Mig6 protein (D) and 
quantifications normalized to actin (E). Mig6 mRNA was measured by qPCR (F). 
Data are reported as means ± SEM; n = 4. *, p < 0.05 vs. LFD.  
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Metabolic regulation of EGFR signaling: As previously discussed, diet-
induced obesity and hepatic ER stress increase Mig6 protein expression and 
decrease EGFR activation (Figures 1-4, 7-11). In addition to HFD studies, 
genetic mouse models of obesity exhibit reduced EGFR expression and 
impairment of regeneration (Collin de l’Hortet et al., 2014). Though the 
investigators utilized growth hormone therapy to restore this impairment, they 
failed to examine the potential impact made by the actions of endogenous 
inhibitors of EGFR. Therefore, we analyzed samples from leptin signaling 
deficient mice for Mig6 expression. db/db mice were obese and hyperglycemic 
compared to littermate db/+ controls (Figure 12- A,B). As expected, EGFR mRNA 
and EGFR activation as measured by phosphorylation of Y1068 were decreased 
compared to littermate controls (Figure12 C-F). Surprisingly, Mig6 mRNA 
expression was decreased in db/db livers (Figure 12-D), perhaps due to the 
cumulative effects of suppressed EGFR signaling (a major stimulus for Mig6 
expression). Mig6 expression is induced by EGFR signaling, yet intact EGFR 
signaling may not be required for Mig6 induction and to avoid confounding 
results, we chose not to use leptin-deficient mouse models in future studies. 
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Figure 12: Mig6 and EGFR expression and activation are decreased in 
leptin deficient mice. 
Eight-week-old db/db and db/+ mice were euthanized, and body weight and fed 
blood glucose were measured (A&B). Livers were extracted and gene expression 
of EGFR and Mig6 was analyzed by qPCR (C&D). Representative Western blot 
shows protein expression (E) and quantification (F). Data are expressed as 
means ± SEM; n = 4, *, p < 0.05 vs db/+. 
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Obesity per se induced Mig6 expression, whereas genetic models of 
obesity reduce EGFR expression and activation. Therefore, we speculated that 
ligand-activated EGFR activity would be decreased in diet-induced obesity. To 
this end, C57Bl/6J mice were injected intraperitoneally with saline or recombinant 
rat EGF and after 10 min the activation of EGFR signaling was assed via 
Western blotting (Figure 13). These results indicate acute EGF ligand stimulation 
will activate EGFR in vivo in a dose dependent manor. To determine the extent of 
which obesity decreases acute EGFR activation in vivo, C57Bl/6 male mice were 
fed either a HFD or LFD control diet for 12 weeks. As designed, HFD fed mice 
develop obesity, fasting hyperglycemia, and glucose intolerance compared to 
controls (Figure 14). Following IP injection of EGF ligand, HFD fed mice had 
paradoxically similar EGFR activation, but reduced downstream ERK activation 
compared to LFD controls (Figure 15). 
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Figure 13: IP EGF injection activates EGFR in C57Bl/6 mice. 
Eight- to ten-week-old mice were fasted overnight (16 h) and administered saline 
or recombinant rat EGF ligand at dose and time indicated. EGFR signaling was 
assessed via Western blot (A) and quantified (B&C). Data are expressed as 
means ± SEM; n = 2-3. *, p < 0.05. 
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Figure 14: Male C57Bl/6 mice are obese and hyperglycemic following HFD 
challenge. 
Six-week-old male mice were fed either a HFD (60% kcal from fat) or LFD (10% 
kcal from fat, matched sucrose) for 12 weeks. Body weight (A) and fasting 
glucose (B) were measured. Glucose tolerance tests were performed following a 
6-h fast; glucose (2g/kg bw) was administered via an IP injection, and blood 
glucose was measured at times indicated (C). Data are expressed as means ± 
SEM; n = 6. *, p < 0.05. 
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Figure 15: EGF mediated ERK activation is decreased in C57Bl/6 mice fed a 
HFD. 
Mice were fed either a HFD (60% kcal from fat) or LFD (10% kcal from fat, 
matched sucrose) for 12 weeks, then fasted overnight (16 h) and administered 
saline or recombinant rat EGF ligand (10 ng/g bw) for times indicated. EGFR 
signaling was assessed via Western blot (A) and quantified (B&C). Data are 
expressed as means ± SEM; n = 3. *, p < 0.05 vs LFD. 
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Generation of Mig6 liver-specific knockout (LKO) mice: EGFR and 
Mig6 are dynamically regulated during feeding and fasting, and acute activation 
of downstream EGFR signaling (i.e., ERK) is decreased during obesity (Figures 
11-15). In addition, obesity-induced ER stress activates Mig6 and decreases 
EGFR phosphorylation, while inducing pro-apoptotic pathways. Therefore, we 
generated Mig6 LKO mice to better define the consequences of Mig6 ablation 
during high fat diet challenge. We utilized mice with a homozygous floxed Mig6 
gene (Jin et al., 2007) crossed with mice expressing Cre recombinase under the 
control of the albumin promoter driven (Postic et al., 1999) to reduce hepatic 
Mig6 mRNA and protein expression in male mouse livers (Figure 16, (Ku et al., 
2012)).   
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Figure 16: Mig6 LKO mice have reduced Mig6 mRNA and protein 
expression in liver. 
Eight-week-old Mig6 LKO and littermate controls were euthanized, and livers 
were analyzed for Mig6 expression. Representative agarose gel images of 
mutant and WT alleles are shown (A). Mig6 mRNA was assessed via qPCR (B). 
Western blots were used to determine Mig6 protein content (C) and normalized 
to actin (D). Data are expressed as means ± SEM; n = 4. *, p < 0.05 vs littermate 
controls. 
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Characterization of Mig6 LKO mice: Eight week old male Mig6 LKO 
mice have similar body weight and overnight fasting glucose compared to 
littermate controls (Figure 17-A,B). Interestingly, Mig6 LKO mice present with 
hepatomegaly compared to controls (Figure 17-C,D). Notably, at eight weeks of 
age glucose and insulin tolerance were similar between Mig6 LKO and control 
male and female mice fed a chow diet (Figure 18). Therefore, we used male mice 
throughout the remaining studies. Although initial metabolic studies indicate 
normal glycemic control in Mig6 LKO mice, further analysis of hepatic tissue 
reveals discrepancies between groups. Importantly, g6pase mRNA expression is 
decreased in Mig6 LKO mice compared to controls at 20 weeks of age (Figure 
19-A). Because g6pase expression is regulated by insulin signaling (Nordlie and 
Foster, 2010), fasting mice were injected with a bolus of insulin, and hepatic 
signaling pathways were analyzed (Figure 19-B). As demonstrated in Figure 19, 
phosphorylation of ERK is markedly upregulated in Mig6 LKO livers regardless of 
insulin stimulation. Importantly, AKT phosphorylation and downstream FOXO1 
phosphorylation are increased in Mig6 LKO livers compared to controls (Figure 
19-B). Even at 20 weeks of age, glucose tolerance tests indicate comparable 
glucose metabolism between groups, however, because the MIg6 LKO mice 
have larger livers (Figure 17-C,D), the total glycogen content is higher compared 
to littermates (Figure 19-C,D). 
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Figure 17: Mig6 LKO mice have hepatomegaly. 
Eight-week-old male mice Mig6 LKO and control littermates were fasted 
overnight. Body weight (A) and blood glucose (B) were measured. Livers were 
immediately extracted and weighed (C&D). Data are expressed as means ± 
SEM; body and liver weight n=5, fasting glucose n = 8-9. *, p < 0.05 vs littermate 
controls. 
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Figure 18: Mig6 LKO mice have normal metabolism. 
Eight-week-old male and female mice were fasted 6 hours prior to GTT. Glucose 
(2g/kg bw) was administered via an IP injection, and blood glucose was 
measured at times indicated (A&B). Following a 5-h fast mice were administered 
an IP bolus of recombinant human insulin (0.75U/kg), and blood glucose was 
measured at times indicated (C). Data are expressed as means ± SEM; n = as 
indicated. *, p < 0.05 vs control. 
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Figure 19: Mig6 LKO livers have normal insulin sensitivity with increased 
total glycogen content.  
After 16 weeks on the diets, male Mig6 LKO and littermate controls were fasted 
overnight, and the livers removed for analysis. g6pase, glucokinase and pepck 
mRNA was assessed via qPCR (A). Western blots were used to determine 
hepatic insulin sensitivity following an IP insulin bolus (5 U/kg bw) (B) and 
quantified (C). Mice were fasted 6 hours prior to an IP glucose bolus (2 g/kg bw), 
and blood glucose was monitored at times indicated (D). Total glycogen was 
extracted from flash frozen livers and enzymatically quantified (E). Data are 
expressed as means ± SEM; n = 3-4. *, p < 0.05 vs littermate controls. 
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Mig6 LKO mice have improved glucose tolerance during a HFD 
challenge: Mig6 LKO mice have hepatomegaly and similar hepatic insulin 
sensitivity compared to controls. Previous studies have reported Mig6 LKO mice 
have decreased liver g6pase and increased glucokinase gene expression (Ku et 
al., 2012). Because g6pase and glucokinase are important regulators of hepatic 
glucose metabolism during obesity, and EGFR and Mig6 expression are 
dynamically regulated during obese mouse models, we fed six-week-old male 
Mig6 LKO and littermate control mice either a HFD or LFD for 16 weeks. Glucose 
tolerance tests performed every four weeks and indicate a trend towards 
improved glucose tolerance among the HFD fed Mig6 LKO and littermate control 
mice, reaching significance by 12 weeks (Figure 20-A-D).  
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Figure 20: Mig6 LKO mice have improved glucose tolerance on a HFD. 
Six-week-old male mice were fed either a HFD (60% kcal from fat) or LFD (10% 
kcal from fat, matched sucrose) for 12 weeks. Following a 6-hour fast, glucose 
(2g/kg bw) was administered via an IP injection, and blood glucose was 
measured at times indicated (A-C). Adjusted area-under-the-glucose-curve 
(AAUC) was calculated after 12 weeks of diet feeding (D). Data are expressed as 
means ± SEM; n = 6-10. *, p < 0.05 vs littermate controls. 
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Discussion: Obesity increases adipose tissue lipolysis and hepatic lipid 
deposition in several mouse models. The effects of various diets and genetic 
backgrounds on NAFLD has been extensively investigated and reviewed (Anstee 
and Goldin, 2006; Petro et al., 2004; Rossmeisl et al., 2003; Surwit et al., 
1995)(Surwit, Anstee, Gajada, Petro, Rossmeisl). Here we examined two widely 
acceptable models of NAFLD in mice, the leptin receptor mutant db/db mice, 
which are severely steatotic and insulin resistant, and HFD-induced obesity (60% 
kcal from fat). First, we discovered that Mig6 gene expression is decreased and 
EGFR expression and activation are nearly absent in the db/db mice (Figure 12). 
This result was disappointing but not completely unexpected, as Mig6 regulates 
EGFR activation and not transcription by evidence of normal EGFR expression 
following Mig6 overexpression studies (Figure 5). Furthermore, leptin signaling 
activates the STAT family of transcription factors, which have highly enriched 
binding sites in the EGFR promoter. Therefore, due to the potential of aberrant 
transcriptional control of EGFR due to the absence of leptin signaling, we chose 
to exclude this mouse model from the remainder of our studies. 
Utilizing HFD fed mice that develop hyperinsulinemia, hyperglycemia, and 
obesity, we discovered Mig6 protein but not mRNA expression is increased in the 
liver. The lack of Mig6 gene induction may indicate an increased stability of Mig6 
protein under stress conditions, as occurs under ER stress in vitro (Figure 8), or 
perhaps enhanced translation. In line with the latter hypothesis, other members 
of our group have demonstrated Mig6 escapes the normal translational blockade 
following stress activation of p-eIF2α, indicating that Mig6 transcripts are 
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preferentially alternatively translated to inhibit EGFR during stress conditions 
(Chen et al., 2013). These data warrant further study on the mechanisms 
regulating Mig6 during obesity.  
We have also determined that acute IP injection of EGF ligand will activate 
EGFR signaling in vivo and that this signaling pathway may be decreased in the 
setting of obesity-induced glucose intolerance. To further explore how this 
pathway is regulated, we generated Mig6 LKO mice. As predicted, Mig6 liver 
ablation induces hepatomegaly and increases hepatic ERK1/2 signaling (Figure 
17,19). Surprisingly, Mig6 ablation improved diet-induced glucose intolerance in 
mice. Here, we have determined a diet-induced mouse model in which to study 
the hepatic consequences of Mig6 ablation during obesity. Initial metabolic 
studies reveal similarities between genders and genotypes on chow (breeder 
chow) diets. However, upon examination of hepatic signaling networks, marked 
differences were observed in hepatic ERK1/2 signaling and possible 
improvements in hepatic insulin signaling when comparing Mig6 LKO mice to 
littermate controls (Figure 19). The possibility of improved insulin sensitivity, as 
evidenced by insulin-mediated AKT and FOXO1 phosphorylation studies as well 
as the significant improvement in glucose tolerance after 12 weeks of HFD, leads 
us to suggest Mig6 may modulate insulin sensitivity in liver. 
Mig6 has recently been implicated in hepatic metabolism through bile acid 
regulation and cholesterol synthesis (Ku et al., 2012). In addition to EGFR signal 
regulation, Mig6 is a known HGF signaling regulator. The HGF/c-met receptor 
has recently been proposed to bind the insulin receptor and act as a regulator of 
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hepatic glucose metabolism (Fafalios et al., 2011). Could Mig6 act through this 
signaling mechanism to regulated glucose metabolism? Or are the effects of 
Mig6 ablation through improvements in hepatic repair mechanisms solely through 
enhanced EGFR activity. The latter is certainly a plausible explanation given the 
increase in downstream ERK1/2 activation seen in Mig6 LKO mice. The next 
chapter will explore the mechanism of Mig6 regulation in liver during the context 
of NAFLD. 
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CHAPTER 5: RESULTS 
Liver-specific mig6 ablation improves glucose tolerance in HFD fed mice. 
Synopsis: Because HFD induces Mig6 protein expression and Mig6 
ablation improves glucose tolerance during a HFD, we utilized this model to 
study the effects of Mig6 ablation during obesity-induced hepatic stress. Here we 
show Mig6 ablation improves glucose tolerance on HFD independent of whole 
body insulin sensitivity or beta cell function. Furthermore, Mig6 LKO mice have 
similar basal proliferation compared to littermate controls. The increase in liver 
weight is not due to increased lipid deposition as determined by similar Oil-Red-
O staining and triglyceride content per mg tissue contrary to previous reports (Ku 
et al., 2012). This observation is divergent to histological findings indicating a 
slight improvement in cell death, as indicated by reduced cellular ballooning. The 
Mig6 LKO mice have higher plasma cholesterol with increased plasma 
triglycerides on HFD compared to littermate controls. Insulin-mediated AKT 
activation is similar among all groups, though the difference in insulin-regulated 
gene expression and improved glucose tolerance suggest improvements in 
hepatic insulin signaling. Taken together these results suggest Mig6 regulates 
hepatic metabolism, yet the precise molecular mechanisms remain elusive. 
Introduction: Hepatic control of glucose production is highly dependent 
upon both substrate and hormone concentrations. During a glucose challenge, 
insulin must activate glucose uptake in skeletal muscle and adipose while 
initiating storage in hepatic tissue. Hepatic nsulin sensitivity is highly dependent 
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upon cellular stress levels. Indeed, ER stress conditions reduced hepatic insulin 
sensitivity lowering metabolic control (Ozcan et al., 2004).  
Previous groups have established that in addition to the insulin receptor, 
EGFR may directly regulate hepatic metabolism by controlling the expression of 
genes involved in gluconeogenesis. Specifically, EGFR signaling suppresses the 
gluconeogenic genes g6pase and pepck. (Fillat et al., 1993; Chan and Krebs, 
1985). Similarly, hepatic EGFR expression is altered during cycles of feeding and 
fasting, possibly aiding in the control of gluconeogenesis (Freidenberg et al., 
1986). In addition to the control of metabolism, EGFR functions as an initiator of 
repair mechanisms ensuring hepatocyte survival during stress conditions (Figure 
10). As discussed in previous chapters, hepatic EGFR activity is decreased 
during ER stress and this activity can be restored by Mig6 ablation. Therefore, 
we sought to determine the extent to which Mig6 ablation would improve hepatic 
metabolism either indirectly through increased survival mechanisms or directly 
through EGFR signaling suppression of gluconeogenic genes.  
Results: Fasting glucose (6 h) and body weights were similar between 
groups throughout 16 weeks of diet (Figure 21-A,B). Notably, glucose tolerance 
after 16 weeks of diet was significantly improved in the Mig6 LKO mice compared 
to littermate controls (Figure 21-C,D). The improvement in glucose tolerance 
were not due to changes in whole-body insulin sensitivity nor gluconeogenesis as 
measured by insulin and pyruvate tolerance tests, respectively (Figure 22-A,B). 
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Figure 21: Mig6 LKO mice have improved glucose tolerance with similar 
fasting glucose and body weights. 
Six-week-old male mice were fed either a HFD (60% kcal from fat) or LFD (10% 
kcal from fat, matched sucrose) for 16 weeks. Fasting glucose (A) and body 
weight (B) were monitored during the diet treatment period. Following a 6-h fast, 
glucose (2g/kg bw) was administered via an IP injection, and blood glucose was 
measured at times indicated (A-C). Adjusted area-under-the-glucose-curve 
(AAUC) was calculated after 16 weeks of diet (D). Data are expressed as means 
± SEM; n = 7-10. *, p < 0.05 vs littermate controls. 
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Figure 22: HFD fed Mig6 LKO have similar insulin and pyruvate tolerance 
compared to controls. 
After 15-16 weeks of diet, mice were fasted (5 h) and insulin (0.75 U/Kg bw) was 
administered via an IP injection, and blood glucose was measured at times 
indicated (A). Following an overnight fast (16 h) mice were administered an IP 
bolus of sodium pyruvate (2 g/kg bw), and blood glucose was measured at times 
indicated (B). Data are expressed as means ± SEM; n = 6-9. *, p < 0.05 vs 
control. 
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Previous studies have demonstrated hepatic ERK signaling can activate 
pancreatic beta-cell expansion, and therefore, increase the insulin secretory 
response in HFD fed Mig6 LKO mice compared to controls (Imai et al., 2008). To 
this end, beta cell mass, fasting insulin and plasma insulin in response to a 
glucose bolus were monitored in HFD fed mice (Figure 23). As reported in Figure 
23, fasting insulin increases on HFD in both groups whereas plasma insulin in 
response to glucose was not different amongst HFD diet groups (Figure 23-A,B). 
Moreover, beta cell area was not different amongst HFD groups (Figure 23-C,D). 
These data indicate Mig6 LKO mice have similar beta cell area, and enhanced 
beta cell function is not responsible for the improvement in glucose tolerance with 
hepatic Mig6 ablation. 
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Figure 23: Mig6 LKO mice have similar plasma insulin and beta cell area 
compared to littermate controls. 
Mice were fasted overnight and plasma insulin was determined from an ultra-
sensitive mouse insulin ELISA (A). Mice were fasted (6 h) and given a bolus of 
glucose (2g/kg bw). Blood samples were procured at times indicated and insulin 
measured (B). Pancreatic tissue was fixed and paraffin embedded. Sections 
were stained for insulin and H&E (C). Beta cell area was quantified as insulin 
positive area divided by total tissue area (D). Data are expressed as means ± 
SEM; insulin and beta cell area n = 4-6, modified GTT n = 7-8. *, p < 0.05 vs 
control littermates. 
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Mig6 LKO mice have hepatomegaly and increased plasma and total 
liver triglycerides on HFD: Following 16 weeks on diet, mice were fasted 
overnight and livers removed for analysis. Livers from Mig6 LKO mice were 
larger in both gross and percent body weight compared to LFD and HFD controls 
(Figure 24-A,B). This enlargement is independent of proliferation, as indicated by 
phosphorylated histone H3 staining, a marker of mitosis (Figure 24-C). The HFD 
similarly induced hepatic hypertrophy in both genotypes, as determined by the 
number of nuclei per 40X field (Figure 24-D).  
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Figure 24: Mig6 LKO mice have hepatomegaly independently of 
proliferation.  
Following 16 weeks of diet, livers were excised and blotted to remove excess 
blood before being weighed (A,B). Tissue samples were fixed in zinc formalin 
and embedded in paraffin wax. Sections were stained for phospho-histone H3 
(PH3) and counterstained with nuclei DAPI stain (C). PH3+ positive and negative 
nuclei were counted in 27 random 40X scans and quantified using ImageJ (D,E). 
Arrows indicate PH3+ cells. Data are expressed as means ± SEM; liver weights n 
= 10, PH3 n = 5-7. p < 0.05 vs control littermates, †, p < 0.05 vs LFD. 
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Previous studies have suggested hepatic Mig6 ablation causes increased 
liver triglyceride (Ku et al., 2012). In our study, however, hepatic Mig6 ablation 
did not increase hepatic triglyceride deposition per se. Biochemical extraction 
and Oil Red-O staining revealed similar hepatic triglycerides and neutral lipid 
content and distribution pattern between groups (Figure 25). However, because 
Mig6 LKO mice have hepatomegaly, the total liver triglyceride content was higher 
when compared to HFD fed littermate controls (Figure 25-B). Although hepatic 
triglycerides were similar between groups, serum triglycerides but not NEFAs 
were increased in Mig6 LKO mice compared with HFD controls (Figure 26 A,B). 
Additionally, plasma HDL levels but not LDL were increased in Mig6 LKO mice 
(Figure 26 C,D) (Ku et al., 2012).  
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Figure 25: Mig6 LKO mice have higher total triglycerides on HFD. 
At 16 weeks of HFD mice were fasted overnight and livers removed. Hepatic 
triglycerides were extracted by chloromethanol extraction methods and measure 
enzymatically (A). Tissues were fixed in paraformaldehyde, dehydrated in 
sucrose, and embedded in OCT. Frozen sections were stained with Oil-Red-O 
and images quantified using ImageJ (B). Total liver triglycerides were determined 
be normalization to total liver weight (C). Data are expressed as means ± SEM; n 
= 5-9. *, p < 0.05 vs LFD. 
95 
 
Figure 26: Mig6 LKO mice have increased plasma triglycerides and HDL 
cholesterol. 
Mice were fed HFD for 16 weeks and fasted overnight before blood was collected 
via cardiac puncture. Plasma triglycerides and NEFAs were measured by a 
colorimetric enzymatic assay (A,B). Plasma HDL and LDL were measured by the 
Translational Core of the Center for Diabetes and Metabolic Diseases at Indiana 
University School of Medicine (C,D). Note the concentration of LDL cholesterol 
was at or below detection levels in our samples. Data are expressed as means ± 
SEM; n = 7-8 *, p < 0.05 vs LFD. 
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Mig6 LKO mice have improved cellular ballooning: Obesity-induced 
hepatic ER stress leads to increased cell death (Wang et al., 2006b), and Mig6 
ablation reduces fatty acid-induced apoptosis in hepatic cell lines (Figure 10). 
More importantly NAFLD is associated with increases in hepatic cell death 
(Feldstein et al., 2003). In order to determine if Mig6 ablation reduces hepatic 
stress during NAFLD, hematoxylin- and eosin-stained liver sections were 
analyzed via the Kleiner method of histological scoring for NAFLD/NASH (Table 
1, Kleiner et al., 2005). Section scoring revealed similar steatosis and low to 
undetectable levels of lobular inflammation (Figure 27-A,B). Interestingly, hepatic 
ballooning was increased in control livers fed a HFD compared to control LFD 
diet, however, no significant increase in hepatic ballooning was observed among 
the Mig6 LKO groups (Figure 27-B), suggesting Mig6 LKO mice were protected 
from liver cell damage and apoptotic death following HFD feeding. The 
composite total hepatic NAS score was similar between the groups, which is 
indicative of the mouse models. Interestingly, the reduction in ballooning dose 
not correlate to a decrease in plasma liver enzymes (Figure 28A-C). In fact, the 
Mig6 LKO mice have a subtle increase in plasma ALT, a measure of liver 
damage, with an increase plasma albumin, a measure of proper function (Figure 
28-D). Although these measurements were significant, the ALT measurements 
do not always correlate with increases in hepatic pathologies (Mofrad et al., 
2003), and the mild elevations in ALT found in LKO mice are markedly lower than 
levels found in true hepatic damage models. 
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Figure 27: Mig6 ablation prevents elevated hepatic ballooning in HFD fed 
mice. 
After 16 weeks of diet, livers samples were fixed in zinc formalin and embedded 
in paraffin wax. Sections (5 m) were stained with H&E (A) scored by a board 
certified veterinary pathologist (B). Scoring methods are listed in Table 1. Arrows 
indicate hepatocellular ballooning. Data are expressed as means ± SEM; n = 
6-11. †, p < 0.05 vs LFD.  
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Figure 28: Plasma ALT and Albumin and elevated in Mig6 LKO mice. 
Mice were fasted overnight and blood was obtained by cardiac puncture at the 
end of the study. ALT, AST, and plasma albumin were measured in plasma by 
the Translation Core of the Center for Diabetes and Metabolic Diseases at 
Indiana University School of Medicine (A-D). Data are expressed as means ± 
SEM; n = 4-6 *, p < 0.05 vs control, †, p < 0.05 vs LFD.  
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Hepatic ERK 1/2 activity is increased in Mig6 LKO mice fed a HFD: To 
determine the mechanism of increased glucose tolerance in Mig6 LKO mice fed 
a HFD, mice were fasted overnight and given an IP bolus injection of insulin. 
Hepatic insulin mediated AKT phosphorylation was decreased in both HFD fed 
groups moreover, Mig6 LKO mice do not have increased AKT activation 
compared to HFD fed controls (Figure 29-A,B). Importantly, the mitogen signaling 
intermediated ERK was highly phosphorylated in Mig6 LKO livers regardless of 
insulin stimulation (Figure 29-C). More importantly still, Mig6 LKO mice on a HFD 
had the highest level of ERK activation (Figure 29-C).  
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Figure 29: Mig6 LKO livers have normal insulin sensitivity following HFD. 
16 weeks after diet, male Mig6 LKO and littermate controls were fasted overnight 
and given an IP isulin bolous (5 U/kg bw). Western blots were used to determine 
hepatic Mig6, AKT, and ERK expression (A). Phosphorylation of AKT and ERK 
were normalized to total AKT and ERK respectively (B,C). Data are expressed as 
means ± SEM; n =4-6 *, p < 0.05 vs control HFD.  
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In addition to protein phosphorylation, insulin regulates gluconeogenesis 
through regulation of gene expression and more importantly, Mig6 LKO mice 
have reduced expression of gluconeogenic genes on chow diet (Figure 20, 
Nordlie and Foster, 2010). Therefore, HFD fed livers were analyzed for glucose 
regulatory gene expression. Mig6 LKO mice had increased glycolytic 
glucokinase, and decreased gluconeogenic g6pase gene expression (Figure 30), 
suggesting the Mig6 LKO mice may have lower HGP than littermate controls. 
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Figure 30: Mig6 LKO mice have increased glucokinase and reduced g6pase 
gene expression on HFD compared to littermate controls. 
Following 16 weeks of HFD mice were fasted overnight and euthanized. Livers 
were removed and qPCR was used to analyze gene expression of glucokinase, 
g6pase, and pepck. Genes were normalized to GAPDH and data are expressed 
as means ± SEM, n=8 *, p < 0.05 vs control. 
 
 
 
 
 
 
 
 
 
104 
Discussion: The notion that Mig6 possesses an additional function as a 
metabolic regulator is recently emerging. Our group has previously described 
Mig6 as a negative regulator of functional β cell mass acting to improve glucose 
homeostasis through increased β cell survival (Chen et al., 2014). However, Mig6 
and its known target EGFR are highly expressed in liver. In fact, EGFR is 
activated following stress from both injury and metabolism (i.e., prolonged 
fasting) (Bhushan et al., 2014; Freidenberg et al., 1986). However, few studies 
have described EGFR’s ability to regulate hepatic metabolism and fewer still 
have examined Mig6’s role. Other groups have recently reported that Mig6 
potentially regulates hepatic cholesterol synthesis, though these studies have 
several methodological concerns (Ku et al., 2012). Here, we demonstrate that 
Mig6 LKO mice exhibit similar body weight and fasting glucose, but have 
enhanced glucose tolerance following the challenge of diet-induced obesity. The 
enhanced glucose tolerance is independent of whole-body insulin and pyruvate 
tolerance (a measure of gluconeogenesis) compared to littermate controls. 
Furthermore, the improvement of glucose tolerance was not ascribed to 
increased functional β cell mass. A previous report described an increase in β 
cell mass mediated by hepatic ERK1/2 activation (Imai et al., 2008), which was 
also present in our mice. Taken together, these results indicate that hepatic 
ablation of Mig6 leads to an inherent improvement in hepatic glucose 
metabolism. 
Liver mass was increased in both LFD and HFD Mig6 LKO mice 
compared to littermate controls (Figure 24 and Ku et al., 2012). These changes 
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do not reflect an increased in hepatic proliferative markers or increased lipid 
deposition indicated by Oil Red O, triglyceride content, and gross anatomy. 
However, the plasma lipid profiles were markedly different among genotypes with 
plasma levels of TG and HDL significantly increased in the absence of Mig6. 
These results are contrary to the improved glucose tolerance, as increased 
plasma triglycerides are a hallmark of obesity-induced diabetes (Solano and 
Goldberg, 2006). The increase in both HDL (LDL was elevated but low in all 
samples) and triglycerides in the Mig6 LKO suggest inherent defects in hepatic 
lipoprotein uptake or hepatic lipase activity. Interestingly, human hepatic lipase 
overexpressing mice have decreased HDL/LDL and serum triglycerides whereas 
knockout mice have higher levels of plasma cholesterol and triglycerides (Dichek 
et al., 1998; Weinstock et al., 1995). Most importantly, hepatic lipase is 
transcriptionally activated by PPAR-γ, which is regulated by EGFR in several 
cancer models (Mansure et al., 2013; Varley et al., 2004). Nevertheless, we can 
only speculate on the potential link between Mig6, EGFR, and hepatic lipase at 
this time. 
EGFR is anti-apoptotic, and NAFLD progression is correlated with 
increased cell death (Feldstein et al., 2003; Paranjpe et al., 2010; Schiffer et al., 
2005; Wieckowska et al., 2006). Because our mice have improved ERK1/2 
signaling, downstream of pro-survival, EGFR, during HFD (Figure 29), we had an 
independent animal pathologist score liver sections using routine NAS scoring 
methods (Kleiner et al., 2005). The Mig6 LKO mice displayed improved hepatic 
ballooning, a measure of cell death, without an improvement in hepatic enzyme 
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markers (Figures 27 & 28). These results were not surprising given the animal 
models used to induce fatty-liver fail to induce necro-inflammation and NASH. 
The slight increase in hepatic ALT levels is consistent with findings that patients 
may have increased enzymatic ALT levels during obesity although these may not 
correlate with severity of NAFLD (Kunde et al., 2005). In order to produce 
massive increases in hepatic cell death and inflammation (NASH) and activation 
of fibrosis a MCD diet may be required. However, as fibrosis is often regarded as 
a proliferative disease, Mig6 ablation may increase the severity of fibrosis and 
lead to cirrhosis.  
Lastly, because insulin resistance and NAFLD exacerbate one another, 
we measured insulin sensitivity in hepatic tissue (Figure 29). We detected no 
significant improvements in insulin-mediated AKT phosphorylation amongst 
groups measured. However, we did identify profound increases in ERK1/2 
activation, regardless of insulin stimulation. The Mig6 LKO mice also have 
improvements in transcriptional patterns of genes involved in hepatic glucose 
metabolism, displaying a gene expression profile reflecting a glycolytic 
phenotype rather than gluconeogenic. These data suggest the insulin sensitivity 
in these mice may be improved as glucokinase, g6pase, and pepck are regulated 
by insulin. In our mice, acute activation studies may not have the power to reach 
significance given the amount of groups analyzed. Another possible explanation 
is the emerging evidence that ERK1/2 may phosphorylate FOXO1 on several 
serine residues in vivo and in vitro (Asada et al., 2007). The regulatory role of 
FOXO1 could explain the transcription of insulin sensitive genes found in our 
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mice. In conclusion, the results described here suggest a novel role for Mig6 in 
regulating glucose metabolism during diet-induced obesity. 
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CHAPTER 6: DISSCUSSION AND FUTURE STUDIES 
Mig6 decreases hepatic EGFR activation and survival during saturated fatty 
acid-induced endoplasmic reticulum stress. 
Summary and perspectives: In Chapter 3, we determined Mig6 was 
activated during chemical- and fatty acid- induced ER stress. We also 
established Mig6 decreases EGFR activation and signaling during hepatic ER 
stress. Furthermore, under stress conditions, Mig6 protein was stabilized and 
Mig6 ablation could restore EGFR activity and reduced caspase 3/7 activity. 
These data suggest a role for Mig6 beyond the classic in utero development and 
oncogenic properties previously described. Mig6 is an early response gene, yet 
many studies fail to recognize the acute function of Mig6 protein, especially given 
the short half-life (1-2 hrs).  
Furthermore, these studies link EGFR signal inhibition to hepatic ER 
stress. Because EGFR is a RTK that activates similar pathways as the insulin 
receptor, we considered the possibility of EGFR resistance during metabolic 
stress. Classically, EGFR over-activation through Mig6 absence is associated 
with hepatocellular carcinoma (HCC) (Reschke et al., 2010). However, during 
hepatic ER stress, repair mechanisms are activated to prevent the damage and 
restore proper cellular function prior to the onset of HCC. In fact, many NAFLD 
patients never develop NASH and therefore, do not progress to cirrhosis and 
HCC (Dixon et al., 2001).  
Most importantly, we do not know the exact mechanisms of Mig6 induction 
during stress conditions. Although Mig6 does escape the translation blockade 
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during ER stress in certain cell lines, the transcription mechanisms still remain 
elusive (Chen et al., 2013). One possible explanation based on in silico analysis 
is through the many ER stress activated transcription factor binding sites in the 
Mig6 promoter, which include NFκB and XBP-1. In this way, Mig6 transcription 
would increase independent of EGFR signaling, which is decreased during ER 
stress. Therefore, Mig6 expression could be controlled independently of EGFR 
activation. 
Future studies: A type of stress common to NAFLD is oxidative stress. 
Originally, oxidative stress was referred to as the secondary hit associated with 
NAFLD progression towards NASH (Day and James, 1998). Another common 
initiator of oxidative stress is the increased oxidation of toxic by-products due to 
drug metabolism by CYP2E1 (Gonzalez, 2005). Clinically, acetaminophen 
overdose induces massive cellular loss due to oxidative stress caused by 
CYP2E1 activity (Manyike et al., 2000). Interestingly, EGFR activation follows 
APAP induced tissue loss in mouse models (Bhushan et al., 2014). We speculate 
that the activation of EGFR would then be regulated by concurrent induction of 
Mig6. Furthermore, following APAP overdose, patients either repair/regenerative 
damaged tissue or enter irreversible liver failure. Therefore, we wondered if 
severe oxidative stress would induce Mig6 gene expression. Using hydrogen 
peroxide (H2O2), a by-product created during hepatic oxidative stress, we treated 
HepG2 cells and induced Mig6 gene and protein expression while decreasing 
EGFR signaling (Y1068) and targets, cyclin D1 and birc5 (Figure 31). These data 
indicate Mig6 may function in a pathological role by controlling oxidative 
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responses. Interestingly, EGFR is thought to be inappropriately regulated by 
activation of pro-apoptotic tyrosine 845 phosphorylation in lung epithelial cells 
(Ravid et al., 2002). This group also reports an inability of EGFR to dimerize and 
internalize into lysosomes during oxidative stress (Filosto et al., 2011), 
suggesting additional roles for EGFR activation during oxidative stress response. 
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Figure 31: Oxidative stress induces Mig6 expression in HepG2 cells.  
HepG2 cells were starved overnight and treated with H2O2 prior to ligand 
stimulation at dose and times indicates. Representative Western blots are shown 
(A). Gene expression was assessed via qPCR normalized to GAPDH and 
quantified (B). Data are expressed as means ± SEM; n = 4. *, p < 0.05 vs. 
untreated. 
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EGFR activation is decreased and Mig6 protein expression is increased 
during obesity in mice. 
Summary and perspectives: The most appropriate model for testing the 
relationship between EGFR and Mig6 during obesity was the 60% HFD model. 
Although, we were able to demonstrate significant increases in Mig6 expression 
in this model, mice fail to develop hepatic pathologies similar to human NAFLD, 
as evidenced by low overall NAS score (Figure 27). The Mig6 LKO mice have a 
larger liver mass than the littermate controls, regardless of diet (Figures 17 & 24). 
This observation is of particular interest because liver transplants from humans 
and of several animal models will expand and contract to reach optimal functional 
size for the recipient (Francavilla et al., 1994; Kam et al., 1987). If liver mass is 
tightly coupled to metabolic demand, then why do the livers of the Mig6 LKO 
expand in both metabolically healthy and compromised individuals? Does the 
increase in parenchymal mass lead to improved liver function via increased 
storage capacity? For example, storing elevated glucose as glycogen or lipids as 
triglycerides, could potentially lower the available substrates or plasma glucose in 
this example. Further studies are need to determine the functional consequences 
of the increased hepatic size in this genetic model. 
However, here we were able to demonstrate for the first time the inhibitory 
effect of obesity-induced NAFLD on EGFR signaling in vivo. These results help 
to establish endogenous feedback inhibitors such as Mig6 as possible targets for 
improving metabolic function during NAFLD. We also have not detected any 
effects of Mig6 towards the development of HCC in any of our models, 
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suggesting that targeting Mig6 alone would not lead to deleterious effects in liver 
as suggested previously (Reschke et al., 2010).  
Future studies: Perhaps the most vital experiment to determine the effect 
of Mig6 on hepatic regeneration is the partial hepatectomy model. This model 
was previously used in Mig6 null mice to determine that Mig6’s regulates cell 
cycle entry following tissue loss (Reschke et al., 2010). However, several groups 
have demonstrated obesity-lowers hepatic regenerative response. In this context, 
hepatic Mig6 ablation could potentially alleviate regenerative restraint. 
Furthermore, partial hepatectomy followed by a functional assay (GTT) may help 
answer some questions regarding liver mass and improved metabolic function. 
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Liver-specific Mig6 ablation improves glucose tolerance in high fat fed 
mice. 
Summary and perspectives: The most impactful data of the project thus 
far is the improvement in glucose tolerance on a HFD. However slight the 
improvement, these data suggest a beneficial role of hepatic Mig6 ablation on 
whole-body physiology. The mechanisms for this beneficial outcome still remains 
elusive. Our data indicates a slight improvement in hepatic insulin sensitivity as 
indicated by gene expression studies, but a direct link is yet to be discovered. 
The improvement in liver health as indicated by lower levels of cellular ballooning 
may prove relevant in improving insulin sensitivity by mere coincidence. Indeed, 
mouse models of NASH development may provide additional information in this 
context.  
 The overall increase in plasma HDL/LDL and triglycerides cannot be 
ignored, as the liver plays a vital role in regulation of plasma lipid regulation. 
These results are in line with previous studies linking Mig6 to cholesterol 
biosynthesis (Ku et al., 2012). However, the cardiovascular effects of these 
changes warrant further study.  
Future studies: As discussed in the introduction, EGF secretion 
increases during the fasting state, however, EGF/EGFR binding and 
phosphorylation are diminished during fasting (Freidenberg et al., 1986). This 
regulation has two possible but not exclusive explanations; first, because EGFR 
signaling suppresses pepck and g6pase, lowering its ligand affinity and activation 
during fasting may be required for transcription of genes necessary for HGP. 
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Secondly, Mig6 is upregulated during fasting and therefore, inhibits EGFR 
activation.  
In addition to obesity, fasting is known to induce ER stress and active pro-
gluconeogenic genes (Wang et al., 2009). Therefore, we sought to determine if 
fasting induced hepatic Mig6 protein expression. C57Bl/6J mice were fasted 24 
hours or re-fed for the last 6 hours and livers examined for Mig6 expression. 
Indeed, Mig6 gene and protein expression are upregulated during fasting 
conditions similar to gluconeogenic g6pase mRNA expression (Figure 32). In 
addition, Mig6 is induced by cAMP in liver (Lee et al., 1985), a secondary 
signaling molecule released during the counter-regulatory response (fasting). 
Mig6 may be regulated by G protein coupled receptors independently of EGFR 
signaling. These data suggest a possible regulatory mechanism for Mig6 during 
fed-fasting transition. However, Mig6 ablation has no effect on fasting glucose 
nor gluconeogenesis (Figures 21 & 22). Although, these studies are not specific 
to hepatic function alone, as the kidneys and intestine retain gluconeogenic 
capacity during extreme fasting conditions. However incomplete, these data 
emphasize the need for strict adherence towards experimental conditions in mice 
as Mig6, a classic EGFR inhibitor, has altered expression levels during metabolic 
duress. 
The best way to determine the contribution of Mig6 liver ablation towards 
whole body glucose metabolism would be through hyperinsulinemic-euglycemic 
clamp experiments. Using isotopic and tritiated glucose, one could determine the 
ability of insulin to stimulate whole-body glucose disposal, increase tissue-
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specific glucose uptake, and suppress endogenous glucose production (a 
measure of HGP). We predict the Mig6 LKO mice would have similar whole-body 
disposal and tissue specific uptake of glucose, but increased insulin-mediated 
suppression of hepatic glucose production. These findings would help define the 
physiological mechanism for improved glucose tolerance. 
 In order to determine the molecular mechanism of improved glucose 
tolerance, we preformed RNA sequencing of liver samples of Mig6 LKO mice and 
littermate controls on both LFD and HFD (Figure 33). At present we have four 
unique data sets indicating separate gene expression patterns within our four 
groupings. A master list of differentially expressed genes revealed differences in 
several genes involved in glucose and lipid metabolism. However, in order to 
determine the functionality of the different gene sets, pathway analysis needs to 
be conducted.  
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Figure 32: Fasting induces Mig6 and g6pase in male C57Bl/6 mice. 
Eight week old mice were fasted (24 h) or refed (24 h fast followed by 6 h feeding 
ab lib). Representative Western blot of liver tissue showing Mig6 protein (A) and 
quantification (B). qPCR of liver tissue showing mig6 and g6pase expression 
(C&D). Data are expressed as means ± SEM; n = 3. *, p < 0.05 vs. Refed. 
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Figure 33: MDS plot showing separation among treatment groups. 
Six-week-old male mice were fed either a HFD (60% kcal from fat) or LFD (10% 
kcal from fat, matched sucrose) for 16 weeks. Following diet livers were 
harvested and flash frozen. RNA was extracted and sequenced. n=4. 
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